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Novel dosage forms were widely investigated in the last decades due to an increased need 
for personalized patient treatment – in this context, oromucosal drug delivery systems offer 
an attractive alternative to the classic oral drug delivery enabling easy administration and 
precise amount of delivered drug. This approach is of particular interest for the pediatric 
population which is subjected to several challenges related to drug delivery including 
difficulties with the swallowing of the solid dosage forms and the lack of appropriate 
medicines on the market.  
The thesis aimed to develop the buccal films and lyophilisates (wafers) based on chitosan as 
a mucoadhesive polymer. Different types of chitosan, solvents (acetic acid, lactic acid, and 
water), and methods of preparation were used (solvent casting and freeze-drying to produce 
films and wafers, respectively) to produce several formulations. Prednisolone was 
incorporated as a model drug in the form of inclusion complexes with hydroxypropyl-beta-
cyclodextrins. The developed formulations were subsequently characterized and compared 
relative to each other for their physical, chemical, and biopharmaceutical properties. 
All the cast films possessed suitable mechanical and elastic properties despite being very 
thin (ca. 50 µm). Their mucoadhesive abilities correlated with the swelling behavior and 
were highest in films containing low molecular weight chitosan, which also was the type 
with the highest degree of deacetylation. Similarly, those films achieved the fastest drug 
dissolution rate with a complete drug release after about 5 hours. The increasing molecular 
weight of the chitosan and changing the solvent (lactic acid to acetic acid) reduced the drug 
release rate from the formulations. Using a mucus-producing HT29-MTX cell line, a good 
permeability of prednisolone through the cell monolayer was proved to indicate a relatively 
high absorption when administered to the mucosal surface. 
The wafers possessed a highly porous structure and were thicker (ca. 0.4 cm) because of the 
lyophilisation process. Their swelling and mucoadhesive abilities were higher compared to 
films, probably due to the increased hydration upon the contact with an aqueous surface. The 
drug release profile from the wafers was comparable between the formulations and was less 
influenced by the composition compared to cast films. 
Overall, the developed formulations possessed good properties and indicate an encouraging 
strategy for controlled drug delivery of the prednisolone to the buccal mucosa. 
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RAZŠIRJENI POVZETEK V SLOVENŠČINI 
Individualna obravnava pacienta je v zadnjih desetletjih povzročila razvoj novih 
farmacevtskih oblik– pri tem so se mukoadhezivni dostavni sistemi za ustno sluznico 
uveljavili kot učinkovita alternativa klasičnim peroralnim farmacevtskim oblikam. Zaradi 
svoje preproste uporabe in varnosti so široko sprejemljivi za paciente, obenem pa omogočajo 
vgrajevanje različnih odmerkov zdravilnih učinkovin. S tem pristopom se želimo približati 
tako pediatrični populaciji, ki se pogosto srečuje z omejeno dostopnostjo ustreznih 
farmacevtskih oblik in odmerkov na trgu, kakor tudi bolnikom, ki imajo težave s požiranjem 
klasičnih trdnih oblik, kot so tablete in kapsule.  
Cilj magistrske naloge je bil razviti in izdelati oralne filme in liofilizate za dostavo 
prednizolona na bukalno sluznico za zdravljenje različnih protivnetnih stanj. Izdelava 
dostavnih sistemov je temeljila na uporabi hitosana kot mukoadhezivnega polimera, pri 
čemer smo razvili več farmacevtskih oblik, ki so se med seboj razlikovale v sestavi. 
Spremenljivke, ki smo jih primerjali med seboj, so bili različni tipi hitosana, topila (ocetna 
kislina, mlečna kislina in voda) in metoda izdelave (metoda izparevanja topila za izdelavo 
filmov ter sušenje z zamrzovanjem za izdelavo liofilizatov). Zanimali so nas štirje tipi 
hitosana, in sicer nizko-, srednje-, in visokomolekularni ter vodotopni hitosan z nižjo stopnjo 
deacetilacije. Za izboljšanje mehanskih lastnosti smo vsem farmacevtskim oblikam dodali 
polietilen oksid in glicerol. Končne farmacevtske oblike so vsebovale 600 µg prednizolona, 
vgrajenega v inkluzijske komplekse s ciklodekstrini, pri čemer je ena odmerna enota 
predstavljala oralni film velikosti 2 cm × 2 cm oziroma okrogli liofilizat s polmerom 0,76 
cm.  
Izdelanim farmacevtskim oblikam smo ovrednotili fizikalno-kemijske in biofarmacevtske 
lastnosti in ocenili pomen posameznih parametrov na njihove končne lastnosti in primernost 
za nadaljnji razvoj. Vrednotenje farmacevtskih oblik je zajemalo določitev njihove trdnosti 
in elastičnih lastnosti, enakomernosti mase in vsebnosti, razpadnosti, nabrekanja, 
površinskega pH, jakosti mukoadhezije in sproščanja prednizolona. Nadalje smo s testi na 
celični liniji HT29-MTX preverili biokompatibilnost, permeabilnost in potencialno 
toksičnost izbranih formulacij in njihovih posameznih komponent. 
Izdelani oralni filmi so bili tanki približno 50 mikrometrov in so tehtali med 25 in 30 
miligramov na posamezno enoto. Izkazovali so dobro trdnost, elastičnost in enostavnost za 
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rokovanje. S pristopom tankih in lahkih filmov se lahko približamo ciljni skupini otrok, za 
katere je še posebej pomembno, da jim aplikacija zdravila ne predstavlja prevelikega 
nelagodja ali bolečin. Liofilizati so imeli primerljivo maso in večjo debelino (med 0,4 in 0,5 
cm) zaradi samega postopka sušenja z zamrzovanjem, a so bili nekoliko manjši in prav tako 
primerni za rokovanje. 
Zaradi uporabe hitosana so izdelane farmacevtske oblike izkazovale dobre mukoadhezivne 
lastnosti; jakost mukoadhezije se je povečevala skladno z nižjo molekulsko maso hitosana. 
Ugotovili smo tudi, da so farmacevtske oblike z mlečno kislino izkazovale močnejšo vezavo 
na sluznico kot tiste z ocetno kislino. Vsi liofilizati so izkazovali močnejše interakcije z 
mucinom kot oralni filmi – te ugotovitve se skladajo s sposobnostjo nabrekanja posameznih 
polimerov. Iz tega lahko sklepamo, da je za vezavo na sluznico ključnega pomena hidratacija 
polimera, saj je s tem omogočena največja možna površina za interakcijo.  
Test razpadnosti je potrdil, da hitosan v fiziološkem okolju ni topen zaradi previsokega pH, 
kar omogoča razvitim farmacevtskim oblikam, da ob aplikaciji ohranijo svojo osnovno 
strukturo. Vseeno pa se začetna masa filmov in liofilizatov v prisotnosti vodnega medija 
precej zmanjša zaradi erozije polimera – ta delež znaša med 20% in 40% po 5 minutah 
izpostavljenosti vodnemu mediju. Iz tega lahko sklepamo, da bi pacienti ob aplikaciji velik 
delež zdravilne učinkovine pogoltnili, nakar bi se prednizolon absorbiral iz prebavnega 
trakta. Tak način absorpcije je sprejemljiv pri sistemski terapiji, saj se zdravilna učinkovina 
skoraj v celoti absorbira. Za zdravljenje lokalnih stanj ustne sluznice pa se farmacevtske 
oblike izkažejo kot manj primerne, saj bi se manjši delež učinkovine obdržal na želenem 
mestu aplikacije.  
Test sproščanja zdravilne učinkovine iz farmacevtskih oblik je pokazal podoben način 
sproščanja pri vseh formulacijah v prvih 30 minutah, pri čemer se je iz farmacevtskih oblik 
sprostilo približno 50% prednizolona. Sproščanje je bilo najhitrejše pri uporabi 
nizkomolekularnega hitosana in ocetne kisline tako pri oralnih filmih kot pri liofilizatih, 
čeprav je pri slednjih ta trend manj izrazit. Nadalje smo ugotovili, da različne sestave 
liofilizatov izkazujejo primerljivo sproščanje. V splošnem se je zdravilna učinkovina iz 
farmacevtskih oblik sprostila v približno 5 urah. 
Biokompatibilnostni test na mukus izločujoči celični liniji (HT29-MTX) ni dokazal velikih 
razlik med posameznimi sestavami na celično viabilnost. Ugotovili smo, da je za celične 
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linije najbolj toksična uporaba obeh kislin, zato se je treba izogibati uporabi visokih 
koncentracij kislin pri dostavnih sistemih na ustno sluznico. Med posameznimi meritvami je 
sicer prihajalo do velikih odstopanj, zato bi za jasne zaključke morali posamezne meritve 
ponoviti. 
Integriteta celične membrane je bila ocenjena med in po izpostavitvi celic testiranim oralnim 
filmom z meritvijo transepitelijske električne upornosti in permeabilnosti paracelularnega 
markerja, pri čemer se je ta ohranila skozi čas izpostavitve izbranim formulacijam. Test 
permeabilnosti je potrdil dobro prehajanje zdravilne učinkovine skozi celično membrano, 
kar nakazuje na dobro absorpcijo skozi bukalni epitelij.  
Na podlagi vseh zbranih rezultatov lahko sklepamo, da izdelani oralni filmi in liofilizati 
izpolnjujejo zahteve za tovrstne farmacevtske oblike, kot so zadostna trdnost in elastičnost, 
primerna velikost in preprostost za rokovanje, mukoadhezivnost, biokompatibilnost, in 
obenem dosegajo prirejeno sproščanje vgrajene slabo topne zdravilne učinkovine. Hkrati pa 
bi bilo treba postopek izdelave izboljšati in prilagoditi, da bi dosegli ustrezno ponovljivost, 
saj so bila med posameznimi meritvami prisotna relativno visoka odstopanja. Tovrstno 
testiranje bi bilo smiselno izvesti tudi na in vivo pogojih in oceniti podobnost s pridobljenimi 
rezultati v izvedeni raziskavi.  
Izdelani oralni filmi in liofilizati so se izkazali primerni za nadaljnji razvoj za dostavo 
zdravilnih učinkovin na ustni sluznici.  
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1.1. ANATOMOPHYSIOLOGY OF THE ORAL CAVITY 
The oral cavity (Figure 1) refers to the space in the mouth including the lining inside the lips 
and the cheeks, the floor of the mouth below the tongue, the front two thirds of the tongue 
and the bony roof of the mouth (the hard palate). It holds an important role in food and drink 
consumption, mastication, communication, and respiration. Being the first segment of the 
digestive system, it is a common site for the administration of several dosage forms, such as 
tablets, capsules, gels and adhesive films (1,2). 
 
Figure 1: The oral cavity (3) 
1.1.1. The structure of oral mucosa 
The alimentary tract, including oral cavity, is lined by a moist mucous membrane (mucosa). 
The oral mucosa is composed of three main layers: epithelium, lamina propria, and 
submucosa (Figure 2). Due to a significant variation in the structures in the oral cavity, the 
buccal mucosa will be discussed later.  
An outermost layer of the buccal mucosa represents the non-keratinized stratified squamous 
epithelium, consisting of 40–50 cell layers reaching a thickness of 500–800 µm with the 
turnover time of approximately 5–6 days. The basement membrane separates it from the 
connective tissue, lamina propria. This layer forms a network of collagen, elastic and nerve 
fibers and is highly vascularized. The blood vessels in the lamina propria lead into the 
internal jugular vein through the lingual, facial, and retromandibular veins, providing a direct 
absorption of the substances through the mucosa. The submucosa is located underneath the 
lamina and represents a looser connective tissue with large nerves, blood vessels and adipose 




Figure 2: The structure of the buccal mucosa; adapted from (1) 
 
1.1.2. Physiological environment in the oral cavity 
Saliva is a watery mixture of fluids responsible for shaping the pH, fluid volume and 
environment of the oral cavity. It is produced and continuously secreted into the oral cavity 
mainly by three salivary glands (submandibular, parotid, and sublingual). The main roles of 
salivary fluid include facilitating the swallowing process, lubricating the oral environment, 
and contributing to the digestion of carbohydrates. Saliva acts like a weak buffer, 
maintaining a relatively constant pH of 5.5–7.0 in the oral cavity. Despite a high turnover 
volume (0.5–2 L daily), only about 1.1 mL is present in the mouth at a time, limiting the 
amount of diluent available for the drug release after an application to the oral cavity and 
potentially compromising the drug bioavailability (6). 
In addition to the saliva fluid, epithelial cells are also covered by the 50–450 µm thick mucus 
layer, an intercellular dense and viscoelastic substance secreted by salivary glands. Mucus 
serves as the first line of defense and is required for the protection against pathogens and 
noxious substances, contributes to the hydration and lubrication of the epithelium and 
facilitates the movement of the cells and substances in the oral cavity. The major part of the 
mucus gel is water (>95%), while the remaining mucus constituents are enzymes, lipids, 
polysaccharides, electrolytes, secretory IgA, lysozymes and mucins, the key components 
responsible for mucoadhesion (1,7). 
Mucins are flexible high molecular weight glycoproteins (0.5–20 MDa) derived from mucus 
secreting cells. These structures form a permeable gel layer enabling the nutrients and gases 
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the transport from the oral cavity towards the underlying epithelium. By forming a highly 
entangled three-dimensional network through physical interactions, covalent and non-
covalent bonds, hydrogen interactions or other specific interactions, and a cohesive and 
highly viscous structure of the mucus is obtained (1,6,8).  
More than 50% of glycoproteins in the mucus represent the carbohydrates, such as galactose, 
fucose, N-acetylgalactosamine and N-acetylglucosamine. Their side chains are covalently 
linked through O-glycoside bonds with the three amino acids – proline, threonine and serine 
– forming a gel-like structure of the mucus. Due to a high amount of sulfate and the sialic 
acid residues present on the glycoprotein molecules, the mucus layer carries a negative 
charge on the surface and behaves as an anionic polyelectrolyte at physiological pH. This 
facilitates the adherence of different substances to the mucosal membrane through the 
interactions with the mucins. Several factors, including pH and ionic strength, are known to 
influence the rheological properties of mucus and subsequently also the drug permeability 
through the mucosal membrane. For example, the mucins possess an extended linear 
conformation in the acidic pH (gel phase) as opposed to the coil conformation at the higher 
pH (sol phase) and have been proven to form aggregates in the environment with a higher 
ionic strength. Consequently, drug delivery through the mucosal surface may be enhanced 
or hindered (8–10). 
 
1.2. CHALLENGES OF DRUG DELIVERY TO THE PEDIATRIC 
POPULATION  
Despite the general acceptability and convenience of oral drug delivery, several patients 
report difficulties related to administration of tablets and capsules, such as discomfort, 
irritation of the pharyngeal region, coughing and choking during the medicine 
administration. It has been estimated that between 20% and 50% of all patients encounter 
such problems, most vulnerable groups being younger children, elderly, handicapped, and 
bedridden patients (11).  
Pediatric population is a widely heterogeneous group, covering neonates from birth to  
adolescents 18 years of age (12). The variability within this group from a physical and 
developmental point of view is known to cause disparities within the pharmacokinetic, 
pharmacodynamic and absorption profile of drugs (13).   
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The medicine requirements for children differ in respect to their age, physiological 
development and/or body weight. However, most formulations are designed and authorized 
primarily to be used by adults and lack the appropriate dosages for pediatric use on the 
market. This often leads to off-label use and modification of the available dosage forms in 
an attempt to provide them with an appropriate dose. Such modifications include splitting 
tablets or opening capsules and mixing the powders with food or liquids. These 
modifications are routinely performed on diverse levels, including at hospital pharmacies, 
and with other healthcare professionals, parents, or caregivers, and are often based on local 
experience instead of evidence. Potential consequences of modifying the dosage forms 
include increased risk for toxicity and/or suboptimal dosing (14–16). 
Since children often deny and resist drug intake, administration of medication is often 
challenging, potentially leading to a poor adherence. During the administration of oral 
dosage forms, younger children experience nausea, vomiting and dysphagia more often than 
adults. Moreover, their acceptance of the medicines is closely related to the medicines’ 
organoleptic and physical properties, including the taste, texture, volume, size, appearance, 
and odor. Unpleasant dosage form properties contribute to rejection of the administration. 
On the other hand, the potential chance for the abuse of “too acceptable” dosage forms with 
a sweet taste and appealing color, similar to candy, must be considered and therefore requires 
an additional effort to avoid drug misuse (13,17,18). 
Additionally, the choice of the pharmaceutical dosage form must be carefully considered 
when targeting groups of children from birth to 10 years of age since their swallowing 
process is not fully developed. For this reason, the use of large oral solid dosage forms should 
be avoided and replaced with alternative medicines when possible (19). 
Due to the mentioned challenges, there is an increasing need for development of new drug 
delivery systems to meet the needs of the pediatric population. To overcome these 
challenges, novel drug delivery systems have been investigated. Despite extensive research 
in this field during the last couple of decades, more information should be obtained to 




1.3. OROMUCOSAL DRUG DELIVERY SYSTEMS 
Oromucosal preparations are a monograph in European Pharmacopoeia (Ph. Eur.) (10.3) 
and are defined as solid, semi-solid or liquid preparations, containing one or more active 
substances intended for administration to the oral cavity and/or the throat to obtain a local 
or systemic effect. The local effect is usually achieved by administration to a specific site 
within the oral cavity (gingivae, the teeth, or the throat) while the systemic effect is a result 
of the absorption through the oral mucosa (such as sublingual drug delivery). A proportion 
of the administered substance may be swallowed and absorbed via the gastrointestinal tract 
(20). 
The oromucosal (particularly buccal) drug delivery has been extensively studied for the last 
couple of years as a promising alternative to the conventional oral drug delivery route. It has 
been shown to be advantageous for the systemic drug delivery both from the 
pharmacokinetics’ and patients’ perspective (6).  
The buccal site is easily accessible and enables the patient to attach the dosage form to the 
administration site easily and also able to remove it in the case of any adverse reactions, 
discomfort, or pain. Since the tissue within the oral cavity is highly vascularized with the 
blood vessels leading directly to the jugular vein, absorbed drugs avoids hepatic first pass 
effect, enzymatic degradation in the gastrointestinal tract and a faster onset of action may be 
achieved. Providing the patient with a controlled, local, and site-specific drug delivery can 
result in diminished gastrointestinal issues related to the oral drug delivery and increased 
patient compliance. Moreover, many drugs are more stable in the relatively neutral pH in the 
oral cavity as opposed to the changing environment throughout the gastrointestinal tract 
(21,22). 
On the other hand, the oral mucosa also has lower permeability and a smaller absorptive 
surface area as opposed to the intestinal area and thus is not able to provide such a rapid 
absorption and acceptable bioavailability for some drugs. The continuous secretion of saliva 
and tongue movement dilute the drug and rinse it from the desired site of absorption, 
followed by swallowing and potential absorption from the gastrointestinal tract. 
Additionally, the unpleasant taste of various drugs can contribute to the lack of patients’ 
adherence, especially in children, and often requires the development of an efficient taste-
masking system. The oral environment differs among individuals and is affected by their 
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eating and drinking behaviour. This can in some cases lead to a high variance in 
bioavailability between the patients, making the development of an appropriate formulation 
more difficult to meet the necessary characteristics (2,21–23). 
The development of drug delivery systems with mucoadhesive properties is a promising 
approach to achieve an improved bioavailability of the administered drug due to increased 
residence and contact time with the mucosal surface as compared to rapidly disintegrating 
oral dosage forms (23). 
 
1.3.1. Bio/mucoadhesion in drug delivery 
Bioadhesion is a general term describing the state in which two materials, at least one of 
them being biological in nature, are held together due to interfacial forces. The term 
mucoadhesion is more specific and is often utilized when the substrate is a mucous layer on 
a surface of epithelial tissue. In the context of drug delivery, mucoadhesion is often referred 
to as the binding of a polymer incorporated in an oromucosal dosage form to a mucosal 
surface (24). 
Two stages are necessary to obtain a mucoadhesive effect of a dosage form: the contact and 
the consolidation (Figure 3). The first occurs by the application of the dosage form to the 
mucosal membrane and is initiated by the patient. At that point, the oromucosal preparation 
hydrates itself while simultaneously dehydrating the mucus layer. Since the mucoadhesive 
preparations do not disintegrate in the contact with the aqueous media, the consequent phase 
is the consolidation phase. The properties of the polymer play a crucial role in this process, 
affecting the hydrating ability of the corresponding dosage form. Dehydration theory 
explains the water migration between the surfaces (dosage form and the mucus layer) until 
reaching the equilibrium (5).  
Adhesion is a complex process that can be explained by several theories – the electronic, 
adsorption, wetting, diffusion, and fracture theory, while it is in practice a mixture of all. 
However, to describe a prolonged interaction between the polymer and the substrate, 
adsorption and diffusion are the most relevant. 
• The adsorption is achieved after a polymer with polar functional groups has come in 
contact with the tissue – polar molecules or groups at the adhesive interface 
reorientate to interact with the negatively charged groups in the glycoprotein network 
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in the mucus. Adhesion is therefore a result of the secondary forces between the two 
substrates and includes hydrogen bonding, Van der Waals forces and hydrophobic 
interactions.  
• The diffusion occurs by physical or mechanical interactions formed when the 
polymeric chains interdiffuse across the adhesive surface into the tissue crevices, 
forming a highly entangled network with the mucin layer. This process occurs 
because of the concentration gradients which drive the polymer chains into the 
bioadhesive matrix until reaching an equilibrium and is additionally influenced by 
the contact time and the polymer properties (the length of molecular chains and their 
mobility) (5,25,26).  
 
Figure 3: Contact and consolidation stage of mucosal adhesion; adapted from (27)  
 
1.3.2. Mucoadhesive properties of polymers 
The presence of a mucoadhesive polymer in drug delivery is crucial to produce a formulation 
that would adhere to the mucosal surface and remain there for a prolonged period. Since 
mucoadhesion is a complex process, several physicochemical properties of the polymers and 
the mucosal structure will influence the adhesion process (25). To choose the optimal 
polymer with respect to the desired site of application and mucoadhesion strength, several 
factors must be considered, including: 
• Functional groups: Polymers possessing hydrophilic functional groups on the 
surface (hydroxyl, carboxyl, amide, sulphate) have generally stronger mucoadhesive 
properties with the mucins compared to neutral polymers. After wetting with the 
saliva, they swell, increase the contact surface with the biological substrate, and 
consequently expose a larger number of hydrophilic groups available for hydrogen 
bonding. Adhesion is additionally influenced by the presence of ionizable groups 
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which may be protonated in the physiological environment, and consequently have 
a higher tendency for interaction with the substrate. 
• Molecular weight: Generally, low molecular weight polymers tend to interpenetrate 
the mucus, while the higher molecular weight proteins favour the formation of 
physical entanglements with the mucins. 
• Cross-linking density and swelling: Lighter cross-linked polymers possess more 
flexible chains and achieve a higher hydration rate, producing a larger surface area 
available for interactions and stronger bioadhesion. Therefore, cross-linking density 
is inversely proportional to the swelling degree. 
• Spatial conformation: Linear conformation (e.g., PEG polymers) is preferred over 
the helical (e.g., dextran) to achieve an appropriate adhesive strength which shields 
many potentially bioadhesive sites. Additionally, the polymer spatial conformation 
is dependent on the pH in the presence of ionizable groups. A repulsion occurs when 
the functional groups are negatively charged, favouring the “rod-like” polymer 
conformation (as opposed to the coiled one) and are consequently more available for 
interdiffusion (7,19,23,25,28).  
 
1.3.3. Mucoadhesive buccal films and wafers 
Mucoadhesive buccal films (MBFs) are oromucosal preparations designed for the use in the 
oral cavity over a longer time period to achieve a local or systemic effect by adhesion to the 
mucosal epithelium (18). The basis for their adhesive properties is the hydrophilic polymer 
which adheres to the buccal mucosa in the form of a hydrogel after wetting with the saliva. 
Generally, they erode with time and do not require the removal. Most commonly, they are 
placed onto the buccal site, but palatal, sublingual, gingival, or labial delivery sites are also 
possible (23,29). Since the cellular turnover time is relatively high (5–6 days), the films  may 
be worn for a longer time, up to several days (21). Due to their small size and volume, the 
amount of drug that can be incorporated is proportionally smaller, making the films more 
suitable for the delivery of drugs with a higher potency (30). 
Oral lyophilisates (wafers) are solid dosage forms of a highly porous nature, obtained by 
lyophilisation (31). By application to the mucosal surface and stepping into contact with the 
salivary fluid, they can regain the swollen gel structure for a longer period of time and enable 
effective drug absorption (32,33). Although some mucoadhesive wafers have been tested in 
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clinical trials, no commercially available examples are available on the market. Currently, 
the oral lyophilisates research is mainly focused on the management of pain and wound 
healing (34). 
The hierarchic representation of mucoadhesive buccal films and wafers according to the 
European Pharmacopoeia (Ph. Eur.) is shown in Figure 4. 
 
Figure 4: The hierarchy of oromucosal preparations according to Ph. Eur. 10.3  
 
1.3.4. Preparation of films and wafers 
MBFs are traditionally prepared by the solvent-casting method or hot-melt extrusion but also 
include more innovative techniques such as the inkjet printing of drugs on an edible substrate 
or film (19). 
Solvent casting is a widely used conventional method with a straightforward manufacturing 
process (Figure 5) and low cost of production. A polymeric solution or suspension with 
adequate rheological properties is prepared. It is desired to be clear, free from air bubbles 
and thus may require deaeration prior to casting to obtain a homogeneous product. The 
polymeric solution is cast (e.g., poured or pipetted) on a suitable material, such as petri dish 
or glass molds, and left to dry at the desired temperature. At the industrial scale, suitable 
rollers are used to spread the film solution onto the substrate. By influencing the height of 
the wet film solution, the final thickness can be controlled. As the solvent evaporates, a 
polymeric film is obtained. The film is subsequently peeled from the surface and cut into 
suitable shape and size according to the intended dosage of the active pharmaceutical 










Figure 5: Solvent-casting preparation of the films 
 
Hot-melt extrusion is an alternative method to solvent-casting and is generally used to 
remove the need for organic solvents. It is based on the modification of the physical 
properties by heating the substance and changing its original form to obtain a desired shape. 
API and excipients are added to the hopper, heated, melted, homogenized, kneaded and 
finally, extruded through the flat extrusion die to obtain homogeneous matrices with a 
desired film shape (Figure 6). Films are produced during the cooling process, cut into desired 
shapes, and packaged. Despite the versatile use of hot-melt extrusion in the pharmaceutical 
field, this method is less commonly used in the production of oral films. One of the main 
limitations of this process is its incompatibility with thermolabile substances (30,35). 
 
Figure 6: Hot-melt extrusion preparation of films (30) 
 
Freeze-drying (lyophilisation) is a method in which the water is removed from the frozen 
matrix by vacuum sublimation, creating a highly porous final product (wafer). The 
polymeric solution is cast on a suitable material in the desired shape and frozen usually prior 
to entering it into the freeze drier. Subsequently, the pressure is lowered, followed by the 
removal of the solvent due to its sublimation and obtaining a solid porous structure, which 




















1.3.5. Characteristics of oral films and wafers 
Ph. Eur. requires the mucoadhesive buccal films to exhibit suitable mechanical strength to 
resist handling without crumbling or breaking (20). Nevertheless, there are no specific 
ranges, parameters or official methods that would evaluate their robustness or strength. 
Several authors in literature perform the mechanical tests and report the information about 
the tensile strength, Young’s modulus, tear resistance, folding endurance and elongation to 
break when characterizing the final film products (36,37). 
To successfully and reproducibly deliver the predetermined amount of drug to the patient, 
the dosage forms must fulfil the criteria regarding uniformity of mass and content. Ph. Eur. 
does not contain an official monograph on the uniformity of mass for oral films and wafers, 
therefore the results are often compared to the requirements for uniformity of mass of single-
dose preparations, particularly tablets.  
Since oromucosal preparations are supposed to be retained on the mucosal surface of the 
oral cavity for a longer period, organoleptic and physical characteristics must be considered 
and optimized. From the patients’ perspective, it is of great importance to develop a 
formulation that would be appealing to the eye, non-irritable on the mucosal surface, and 
have a pleasant taste, odor and mouth feel (18).  
Additionally, mucoadhesive films should possess mucoadhesive properties while handling 
the constant saliva rinse and movement of the tongue within the oral cavity. This information 
may be estimated by water sorption determination or mucin-interaction test to evaluate the 
tendency of the formulations to interact with mucosal surface (36). 
 
1.3.6. Composition of the oral films and wafers in the current study 
1.3.6.1. Chitosan 
Chitosan is a natural linear polysaccharide copolymer of deacetylated β-(1-4)-linked D-
glucosamine and N-acetyl-D-glucosamine, obtained by alkaline N-deacetylation of chitin 
(Figure 7). It is derived from the shells of crustaceans such as crabs, shrimps, and crawfish, 
exoskeleton of arthropods, and cell walls of some fungi (38).  
The presence of –OH and –NH2 groups allows chitosan to exhibit hydrogen and covalent 
bonding. Due to the amino groups within the polymer structure, chitosan is protonated in the 
acidic media below its pKa=6.5. The repulsion between the positively charged molecules 
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alters its chain conformation from a rigid to a semiflexible state, enabling it to form 
electrostatic interactions with polyanions (40,41). Its ability to interact with negatively 
charged structures in the mucus, such as sialic acid, results in strong mucoadhesive 
properties (42). 
 
Figure 7: The chemical structure of chitin and chitosan (39) 
Chitosan has been extensively used and investigated in the pharmaceutical field due to a 
large number of its unique biological properties, including biocompatibility, 
biodegradability, and nontoxicity for mammals (43). Additionally, it promotes the 
paracellular transport of molecules across the epithelium by binding to the integrins αvβ3 
present on the epithelial surface. By activating a group of kinases (focal adhesion kinase and 
Src tyrosine kinase), tight junctions are temporarily opened, and the substances permeate the 
epithelial barrier easier, enhancing the systemic drug absorption and bioavailability (40).  
A high variety within the polymer family is exhibited due to their differences in the degree 
(DDA) and pattern of deacetylation, affecting behaviour of the polymer in the solution. 
Chitosan is normally 80–95% deacetylated in a “block-wise” pattern with a heterogeneous 
distribution of the remaining acetyl groups (44). It is insoluble in water and organic solvents 
and soluble in dilute aqueous acidic solutions (40).  
By re-acetylation of fully deacetylated chitosan, a controlled and homogeneous distribution 
of glucosamine-N-acetyl residues may be obtained to achieve a controlled, lower DDA 
(Figure 8) (45). It has been shown that solubility in the neutral pH can be achieved by 
controlling the fraction of acetylated units (46). A commercially available representative of 
the homogeneously deacetylated chitin is ViscosanTM (47). Its mucoadhesive properties have 
been studied in the last decades to produce novel drug delivery platforms to prolong the 
retention of various drugs on the mucosal surfaces. The mucoadhesiveness can be affected 





Figure 8: Distribution of acetyl groups in chitin and chitosan; adapted from (47). 
To study the effect of these parameters on the drug delivery systems, four types of chitosan 
were used and compared relative to each other in the Master’s thesis and are summarized in 
Table I. 
Table I: Chitosan types used in the research 
Chitosan Molecular weight (Mw) DDA Characteristics 
Chitosan CM Not specified 98% Low Mw chitosan 
Chitosan M 570 kDa 89% Medium Mw chitosan 
Chitosan L 720 kDa 90% High Mw chitosan 
ViscosanTM Not specified 50% Water-soluble 
 
1.3.6.2. Plasticizers  
Plasticizers are low molecular weight molecules that are often added to film solutions to 
improve the films’ mechanical properties. By incorporating themselves within the film-
forming polymer chains, intermolecular forces along the chains are weakened and the glass 
transition temperature (Tg) is lowered. This leads to increased polymer chain flexibility and 
hence improved film flexibility and elasticity. Glycerol, propylene glycol and low-
molecular-mass macrogols are examples of common constituents of oral films. Additionally, 
the plasticizing effect may be achieved by the remaining water in the final product, 
contributing to the elasticity of the films (48,49). 
Poly(ethylene oxide) (PEO) is a non-ionic hydrophilic polyethylene glycol which has been 
reported to produce oral films with good mechanical resistance and fast dissolution rate. Due 
to its low Tg, it can form a self-plasticizing matrix, diminishing the need for additional 
plasticizers to be incorporated. Another advantage of this polymer is a pleasant mouth feel, 




1.3.6.3. Prednisolone  
Prednisolone (Figure 9) is a synthetic corticosteroid prominently used in the therapy of 
asthma, allergies, rheumatic arthritis, hepatitis, leprosy, and other chronic inflammatory and 
autoimmune conditions. Its anti-inflammatory effect is primarily achieved by the inhibition 
of production of prostaglandins and leukotrienes (36). 
Prednisolone is a neutral molecule providing no acidic or basic functional groups and is very 
slightly soluble in water (223 mg/L at 25 °C) due to its highly lipophilic structure 
(logP=1.60). According to the Biopharmaceutics Classification System (BCS), the drug 
substance belongs to the “Class 1” (high solubility and high permeability). The basis for this 
classification is the dose/solubility ratio and since the drug is potent, low doses are required. 
Since the highest dose (50 mg) is soluble in 250 mL of water over the pH range of 1–6.8 at 
37 ± 1°C, the criteria for high solubility is met. The oral administration of the substance 
results in a high bioavailability ranging between 80 and 100%, reaching the maximum 
systemic concentration within 1–3 hours after administration (51–54). 
 
Figure 9: The chemical structure of prednisolone 
Prednisolone is usually delivered via the oral route. Since the treatment with prednisolone 
has a wide spectrum of local and systemic conditions and diseases, the optimal dose is 
dependent on the nature and severity of the conditions (53). The dosage form strength on the 
market generally varies from 1 to 50 mg. Despite the wide therapeutic index, the frequency 
and intensity of adverse events is higher with the increasing dose. Most commonly, the dose 
of prednisolone is 5–7.5 mg/day but is dependent on the nature and severity of the disease 
and should be therefore personalized. However, the drug bioavailability seems to have a high 
variance when administered orally, and additionally possesses a short biological half-life 
(approximately 2–4 hours) (51,55,56). 
An alternative approach to the widely used prednisolone tablets would be a sustained buccal 
delivery that could provide a controlled release of the drug over a prolonged period and 
reduce the probability for adverse effects (53).  
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1.3.6.4. Cyclodextrins   
Cyclodextrins (CDs) are cyclic oligosaccharides consisting of hydrophilic outer surfaces and 
lipophilic central cavities, which can incorporate lipophilic molecules (guest molecules) 
within their structure. They may be distinguished with respect to their composition and 
consequently the size of the lipophilic cavities, affecting the formation and properties of the 
complex with the guest molecule. Natural CDs are α-, β- and γ-CDs, composed of 6, 7 and 
8 glucopyranose units, respectively (57).  
Several types of cyclodextrins have been commonly used as pharmaceutical excipients to 
increase the drug solubility, bioavailability and/or stability of poorly water-soluble drugs, 
but may be also used to reduce gastrointestinal or ocular irritation, mask unpleasant taste or 
prevent interactions with other molecules (58). The maximum drug loading has been shown 
to be enhanced with the hydroxypropyl-β-cyclodextrins. Additionally, the taste-masking 
effect may be achieved, which can be especially beneficial for incorporation of bitter-tasting 
drugs, such as prednisolone (59,60). 
 
1.3.6.5. Solvents 
The use of solvents in film or wafer production is generally chosen based on the solubility 
of APIs or excipients in the corresponding solvent. Water or diluted acids are often 
appropriate for dissolving the polymers; however, the addition of organic solvents is 
sometimes required to dissolve the API and/or the excipients. Since organic solvents may be 
hazardous, the assessment of residual solvent in the final product must be carried out when 
those are used (13). In the present study, acetic acid and lactic acid were used to dissolve 





2. AIMS AND OBJECTIVES 
The overall aim of the Master’s thesis is the development and characterization of chitosan-
based mucoadhesive oral films and lyophilisates (wafers) for the buccal delivery of 
prednisolone. The novel formulation should provide a user-friendly dosage form assuring 
the mucoadhesive properties and enable an increased residence time on the buccal mucosa. 
This approach is of particular interest for the treatment of inflammatory diseases in the 
pediatric population to overcome the challenges related to the oral administration of solid 
dosage forms and, thus, potentially improve patients’ compliance.  
Prednisolone will be incorporated into inclusion complexes with hydroxypropyl-β-
cyclodextrins to increase the drug solubility and mask its bitter taste. To optimize the 
composition of films and wafers, several parameters will be tested and the most appropriate 
will be further used to produce and evaluate the dosage forms.  
By using two methods of preparation – solvent casting and freeze-drying – we will obtain 
buccal films and wafers, respectively. Four types of chitosan (possessing different molecular 
weights and degree of deacetylation) and different solvents will be used (lactic acid, acetic 
acid, and water) to obtain the final products. Poly(ethylene oxide) will be used as a plasticizer 
and an additional taste-masking agent. 
A single dose unit will be considered a 2 cm × 2 cm film piece or a round wafer with a radius 
of r=0.76cm. The final products will be evaluated for their physical, chemical, and 
biopharmaceutical properties and additionally tested on mucus-producing cell line HT29-
MTX to carry out the biological evaluation of the product.  
The goal of the project is to establish a reproducible film and wafer preparation technique 
for the chosen formulations that would exhibit adequate properties and be potentially used 




3. MATERIALS AND METHODS 
3.1. MATERIALS 
Material Producer 
Acetic acid glacial VWR Chemicals, France 
Calcium chloride dihydrate Merck, Germany 
Cavasol W7HP Pharma, Mw=1400g/mol Wacker Chemie AG, Germany 
Chitopharm CM – DDA 98%, Mw: not specified Chitinor AS, Norway 
Chitopharm L – DDA 90%, Mw: 720 kDa Chitinor AS, Norway 
Chitopharm M – DDA 89%, Mw: 570 kDa Chitinor AS, Norway 
Dimethyl sulfoxide (DMSO) Merck, Germany 
DL-Lactic acid, 85% Sigma Aldrich, USA 
DMEM (1X) + GlutaMAXTM,  Gibco, UK 
Foetal Bovine Serum (FBS) Sigma-Aldrich, USA 
Glycerol 85% Apotekproduksjon AS, Norway 
HBSS Sigma Aldrich, USA 
Hydrochloric acid 37% Merck, Germany 
HT29-MTX cell line kindly provided by Dr. Thécla 
Lesuffleur (INSERM UMR S 
938), France 
Methanol VWR Chemicals, France 
Mucin from porcine stomach, Type 2 Sigma Aldrich, USA 
Non-Essential Amino Acid Solution (NEAA) Sigma Aldrich, UK 
Penicillin  Sigma Aldrich, USA 
Phosphate buffered saline tablet Sigma Aldrich, USA 
Poly(ethylene oxide) Sigma Aldrich, USA 
Potassium chloride Merck, Germany 
Prednisolonum micronisatum Fagron, Denmark 
Sodium chloride, AnalaR NORMAPUR VWR Chemicals, France 
Sodium dihydrogenphosphate monohydrate Merck, Germany 
Sodium hydrogencarbonate VWR Chemicals, France 
Sodium hydroxide, pellets Sigma Aldrich, USA 
Streptomycin Sigma Aldrich, USA 
Thiazolyl Blue Tetrazolium Bromide Sigma Aldrich, USA 
Transwell inserts Corning Costar, USA 
Trypan Blue stain 0,4 %, Invitrogen Thermo Fischer Scientific, USA 
Triton-X Merck, Germany 
Ultra-purified water Merck Millipore, Germany 




Centrifuge, Model 4200 Kubota Corporation, Tokyo 
CountessTM automated cell counter Invitrogen, USA 
DSC, DSC822 Mettler-Toledo, USA 
Freeze drier, Alpha 2-4 Christ, Germany 
Cell culture Incubator, CCL – 170B – 8  ESCO, Singapore 
Micrometer, Mikrometer Cocraft Clas Ohlson, Sweden 
Orbital Shaker-Incubator ES-20 Biosan, Latvia 
pH meter: Mettler Toledo Five easy F20 Mettler Toledo, Switzerland 
Scales, Santorius Research R160P balance,  Richmond Scientific Ltd.., 
England 
Texture analyser Ta-XT2i Stable Micro Sytems, Godalming, 
UK 
UV-VIS spectrophotometer, UV-1600PC ECN 
634-6001 
VWR Chemicals, France 
Viscosimeter Brookfield DV2T Viscosimeter 
with the spindle CPA-52Z 
Brookfield, USA 
Volt/Ohm meter, Millicell® ERS-2 EMD Millipore, USA 
Water bath, SUB AQUA 12 Grant instruments (Cambridge) 
Ltd, England, UK 
 
3.2. SOLUTIONS 
➢ 1% V/V acetic acid: 1% (V/V) acetic acid was prepared by adding 10 mL of glacial 
acetic acid to a flask with 900 mL of deionized water, filling it up with water to 1 L 
and stirring before use.  
➢ 1% V/V lactic acid: 1% (V/V) lactic acid was prepared by adding 11.1 mL of 85% 
lactic acid to a flask with 900 mL of deionized water, filling it up with water to 1 L 
and stirring before use.  
➢ Cell culturing medium: 50 mL of FBS, 5 mL of Penicillin (100 units/mL) + 
Streptomycin (100 µg/mL) and 5 mL of Non-Essential Amino Acid (NEAA) cell 
culture supplement were aseptically added to 500 mL of Dulbecco’s Modified Eagle 
Media (DMEM) and mixed well before use. 
➢ Mucin dispersion 3% w/w: 3 g of mucin from porcine stomach was dissolved in 97 




➢ 0.01 M phosphate-buffered saline (PBS), pH=7.40: 0.01 M phosphate-buffer 
saline was prepared by dissolving one PBS tablet in 200 mL of deionized water. pH 
of the solution was adjusted to 7.40 with 0.1 M NaOH. 
➢ Saliva substitute (SS), pH=6.80: Saliva substitute was prepared as described by J. 
Alopaeus et al. (29) by dissolving 0.21 g NaHCO3, 0.43 g NaCl, 0.75g KCl, 0.22 g 
CaCl2 • 2H2O and 0.91 g NaH2PO4 • H2O in 1 L of deionized water to mimic the 
physiological environment in the oral cavity. The final pH was adjusted to 6.80 with 
0.1 M hydrochloric acid.  
 
3.3. METHODS 
3.3.1. Phase solubility of prednisolone in HP-β-CD 
To determine the inclusion complexation of prednisolone (PN) with hydroxypropyl-β-
cyclodextrin (HP-β-CD), solutions with predetermined concentrations of HP-β-CD (0, 2, 4, 
6, 8 and 10 mM) in the distilled water were mixed with an excess of PN in glass vials and 
stirred at 300 rpm for 72 hours at room temperature (RT) to achieve association equilibrium 
and obtain saturated inclusion-complexes. Each sample was prepared in triplicate. The 
solution was filtered through a 0.45 μm syringe filter to remove any excess of the 
undissolved drug and was subsequently diluted with methanol: water = 1:1 mixture to 
release the drug from the complex. Prednisolone in the filtered solution was quantified by 
UV-VIS spectroscopy at the wavelength λ=240 nm using the calibration curve. The 
calibration curve (R2>0.99) was determined using a 5-point calibration covering the PN 
range between 0 and 20 μg/mL, each measured in triplicate.  
The solubilising ability of HP-β-CD was determined by calculating the complex formation 
constant (K1:1; Equation 1), the complexation efficiency (CE; Equation 2) and PN:CD 
complexation molar ratio (Equation 3) where S0 represents the intrinsic solubility of PN and 
slope represents the slope of the linear curve obtained by plotting PN concentration against 
HP-β-CD concentration (61). 
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The obtained molar ratio was used to produce films and wafers with prednisolone 
incorporated in the complexes. The solubility of prednisolone was tested in other media (1% 
V/V lactic acid, 1% V/V acetic acid and saliva substitute) by mixing an excess of PN to each 
of the media without and with corresponding amount of HP-β-CD according to the procedure 
described above. The PN solubility in the tested media was compared to the previously 
obtained solubility in the distilled water. 
 
3.3.2. Preparation of the film solutions 
The same film solutions were prepared to produce both films and wafers. The total mass of 
wet film solutions was 100 g for each batch. 
Film solutions containing chitosan CM, M and L, were prepared by premixing prednisolone 
and the corresponding amount of HP-β-CD (according to the determined molar ratio) in the 
solvent and stirred overnight at RT. The rest of the components – chitosan, PEO, and glycerol 
– were added the following day and the solution was stirred for another 24 hours to obtain a 
homogeneous and clear solution. Additionally, the solution was sonicated for 15 minutes to 
remove the entrapped air bubbles. All components and their final amounts in the final 
optimized formulation are summarized in Table II. 
Viscosan (water-soluble chitosan) film solution was prepared according to the procedure 
prescribed by the provider. Viscosan was dissolved in approximately one-half amount (48 
mL) of the distilled water. 2 mL of 2 M HCl was added dropwise and the solution was left 
to stir for 15 minutes at RT. The second half of the water (48 mL) was added, and the solution 
was stirred overnight for the polymer to be fully dissolved. 2 mL of 1 M NaOH was added 
dropwise and stirred until completely homogeneous (about 2 hours). Prednisolone and HP-
β-CD were subsequently added along with glycerol and PEO, and the final solution was 




Table II: Final composition of the wet film formulation 
Constituent Material Qualities Final content 





Additional polymer and plasticizer Poly(ethylene 
oxide) (PEO) 
PEO 100 0.20% (w/w) 
Plasticizer Glycerol - 1.00% (w/w) 
Drug Prednisolone Crystalline 0.10% (w/w) 
Solubility enhancer and taste masker HP-β-CD - 0.80% (w/w) 
Solvent Acetic acid 
Lactic acid 
Water 
1 % (V/V) 
1 % (V/V) 
Distilled 
up to 100% 
(w/w) 
 
3.3.3. Preparation of the films and wafers 
Films were produced using the solvent casting method – 23 grams of the film solution was 
cast onto a 20 cm x 20 cm square petri dish. Films were allowed to dry on a flat surface 
protected from light at RT for 72 hours and were subsequently cut using a ruler and a surgical 
knife into square pieces where 2 cm × 2 cm was defined as a single-dose unit.  
Wafers were obtained from the same film solutions by the freeze-drying method. A 
predetermined amount of film solution (0.60 g) was pipetted into each well of a 24-well 
plate. The plates were frozen overnight at –20 °C and subsequently freeze-dried for 24 hours 
at 20 °C at 0.045 mbar (Figure 10). The wafers were removed from the wells, where one 
round piece was considered a single-dose unit (radius=ca. 0.76 cm).   
 
Figure 10: Freeze drying of wafers 
Films and wafers were stored in a desiccator (over saturated MgCl2 • 6H2O, relative 
humidity=33.2–33.6%) until further use to equilibrate the moisture absorption before 
carrying out the studies. 
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3.3.4. Formulation optimisation  
Different parameters were screened and compared to optimise the formulation and obtain 
the final composition (Table II) of the wet formulations and the preparation procedure. This 
was done in steps, and the factors tested were the polymer ratio (chitosan/PEO = 1/1; 9/1) 
and the presence of glycerol (0, 1, 2 and 4% w/w). Finally, the preparation methods (mould 
and surface) and size of the dose-unit (diameter and thickness) were optimised. A schematic 
overview of the optimisation process is presented in Figure 11. 
 
Figure 11: Optimisation process before final testing 
 
3.3.4.1. DSC 
The DSC (Dynamic Scanning Calorimetry) analysis was performed to select a suitable 
mixing ratio of the two polymers and to determine the thermal stability of the polymer 
mixtures. A piece of film containing only polymers (chitosan and PEO) in the corresponding 
media (2.00–2.50 mg) was weighed in an aluminium pan and covered with a lid. DSC 
measurement was carried out under nitrogen atmosphere. Each sample was analysed under 
the following conditions: they were held at –30 °C for 2 minutes and then heated to 200 °C 
at a heating rate of 10 K/min. Indium was used as a reference to calibrate the temperature 
scale. The curve obtained was normalized to the mass of the film.  
 
3.3.4.2. Overview of finally prepared formulations  
The chosen composition (Table II) was used to produce oral films and wafers with all the 
four polymers and corresponding solvents. A summary of the finally prepared formulations 
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Table III: A summary of produced formulations and their respective names 
Formulation Abbreviation Method of 
preparation 
Chitosan type Solvent 
F1 CM ace Solvent casting Chitosan CM Acetic acid 
F2 CM lac Solvent casting Chitosan CM Lactic acid 
F3 M ace Solvent casting Chitosan M Acetic acid 
F4 M lac Solvent casting Chitosan M Lactic acid 
F5 L ace Solvent casting Chitosan L Acetic acid 
F6 L lac Solvent casting Chitosan L Lactic acid 
F7 Visco Solvent casting Viscosan Water 
F8 CM ace FD Freeze drying Chitosan CM Acetic acid 
F9 CM lac FD Freeze drying Chitosan CM Lactic acid 
F10 M ace FD Freeze drying Chitosan M Acetic acid 
F11 M lac FD Freeze drying Chitosan M Lactic acid 
F12 L ace FD Freeze drying Chitosan L Acetic acid 
F13 L lac FD Freeze drying Chitosan L Lactic acid 
F14 Visco FD Freeze drying Viscosan Water 
 
 
3.3.4.3. Visual and sensory inspection of the films and wafers 
Simple sensory tests were performed to determine the appropriate level of glycerol as well 
as size and thickness of the products.  
After the films had been dried, they were inspected visually e.g., colour, stickiness, 
smoothness of the surface. The film should allow handling, not feel sticky nor be too brittle 
and crack upon cutting or folding. Neither the films nor the wafers should be too thick as 
that would be uncomfortable in the mouth, but too thin preparations would be difficult to 
handle. 
The optimisation of the wafer preparation and size was obtained by pipetting different 
amounts of wet solutions into the wells during the preparation (0.30 g, 0.60 g, 0.90 g, 1.20 
g, 1.50 g, 1.80 g) and assessing the appropriate size for a wafer as a dosage form. The film 
casting method was initiated with 23 grams of the well solution per petri dish and was 




3.3.5. Physicochemical and biopharmaceutical characterization of formulations  
3.3.5.1. Viscosity of wet film solutions 
The dynamic viscosity of wet film solutions was determined by a single-point measurement 
using a Brookfield Viscosimeter with the spindle CPA-52Z at 25 °C. 500 µL of the solution 
was added and the sample was allowed to equilibrate for 2 minutes prior to the test. The 
samples were measured in triplicate at the speed of 0.8–30 rpm. The average solution 
viscosity and the standard deviation (SD) were calculated. 
 
3.3.5.2. Uniformity of mass and thickness of the formulations 
Since Ph. Eur. does not contain an official monograph uniformity of mass for oral films or 
wafers, the Ph. Eur. 2. 9. 5. Uniformity of mass of single-dose preparations for Tablets 
(coated or uncoated) with an average mass of 80 mg of less was employed. 
20 randomly selected single-dose units of films were weighed one by one. Not more than 
two films were to deviate from the average mass by more than 10 percent and none more 
than 20 percent.  
In addition to films, 10 wafers were weighed (lower number due to a smaller number of 
wafers produced). Not more than one wafer was to deviate more than 10 percent from the 
average mass and none more than 20 percent.  
The film thickness was measured on 20 randomly selected units in the centre of each with 
the micrometre screw and the average thickness was recorded. Similarly, the wafer thickness 
was measured on 10 randomly selected units. Their initial thickness was noted as they were 
strongly subjected to the mechanical deformation when applying pressure.  
 
3.3.5.3. Drug content and uniformity  
A single-dose unit was placed in 50 mL of mixture methanol: water = 1:1 and stirred for 10 
minutes and sonicated for 20 minutes to ensure that the drug was completely dissolved from 
the inclusion complex. The drug content was determined by UV-VIS spectroscopy at the 
wavelength λ=240 nm. Linearity of the standard curve was confirmed using a calibration 
curve with the PN concentration range between 2.5 and 20 µg/mL – for this purpose, the 
same polymer matrix as present in the single-dose unit content was added to the reference 
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solution to eliminate the effect of the background (the potential absorbance of the polymers 
themselves). Five parallels were measured for each formulation and 3 measurements were 
repeated for each while the average was recorded.  
Concentration was determined from the calibration curve equation obtained (Equation 4) 
and the total mass of prednisolone along with the SD per film or wafer piece was calculated 
using the Equation 5: 
 𝐴 =  𝑘 ×  𝑐 +  𝑛 Equation 4 
 𝑚 = 𝑐 × 𝑉 Equation 5 
Where A is absorbance measured, k is slope of the calibration curve, n is the initial value on 
the curve, c is the calculated concentration in the solution and V is the volume of the 
methanol: water mixture. 
 
3.3.5.4. Puncture strength and elasticity of the films 
The test is modified from Preis et al. (23) and was conducted on the Texture Analyzer to 
analyse the mechanical properties of the film formulation. A single dose piece unit was 
placed into the stationary sample holder and fixed with four wingnuts (Figure 12).  
 
Figure 12: Film sample holder scheme (left) with explained parameters (right) (37) 
 
A flat-faced cylindrical probe (rprobe = 3.52 mm, A= 38.8 mm
2) moved from the upper part 
of the Texture analyzer with the speed of 2.0 mm/s downwards toward the film (trigger force 
F=0.05 N) and reduced to the test speed of 0.1 mm/s after having touched the film. 
Displacement (the distance) for the film to break was recorded and the software calculated 
the force exerted on the film at the breaking point. 
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The test was performed on 5 separate units in total per film formulation. Wafers were not 
included in the test as their shape was not compatible with the method. 
Puncture strength (N/mm2) and elongation to break (%) were calculated according to the 







𝐴𝑟𝑒𝑎 𝑜𝑓 𝑡ℎ𝑒 𝑝𝑟𝑜𝑏𝑒 (𝑚𝑚2)
 Equation 6 
 
𝐸𝑙𝑜𝑛𝑔𝑎𝑡𝑖𝑜𝑛 𝑡𝑜 𝑏𝑟𝑒𝑎𝑘 (%) = (
𝑟𝑝𝑟𝑜𝑏𝑒+√𝑎`2+𝑏2
𝑟𝑠𝑎𝑚𝑝𝑙𝑒
− 1) × 100 Equation 7 
 
Where rsample is the initial length of the film sample in the holder (6.985 mm; see Figure 12), 
a’ is the difference between the initial length of the film and the radius of the probe (=rsample 
– rprobe), b is the vertical displacement of the probe at the breaking point and r is the radius 
of the probe (3.52 mm). 
The statistical difference of mechanical properties between the samples was calculated using 
a paired one-tailed t-test with the significance level p<0.05.  
 
3.3.5.5. Film disintegration 
A single-dose piece of formulation (film or wafer) was immersed into a beaker containing 
50 mL of saliva substitute (pH=6.80), incubated at 37 °C and shaken at 60 rpm for 3 hours 
to imitate the movement of the tongue in the mouth. During the experiment, films and wafers 
were inspected to see whether they disintegrated to the point when no visible traces of 
coherent matrix was visible. In the case of disintegration, the time until complete dissolution 
was recorded. Three parallels were tested for each formulation. 
 
3.3.5.6. Swelling and erosion test 
The swelling and erosion test were conducted on 3 parallels of each single-dose unit to assess 
the swelling behaviour of the polymers and erosion of the material occurring due to contact 
with the aqueous media. A single-dose piece of film or wafer with the predetermined mass 
(m1) was placed in a petri dish, immersed in 5 mL of saliva substitute (pH=6.80) and allowed 
to swell for 5 minutes at RT. Its weight (m2) was recorded after gently wiping the product 
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with a piece of paper to remove the surface water. The swelling index represents the weight 
gained in respect to the weight of a completely dry film and was calculated according to the 
Equation 8. 
 𝑆𝑤𝑒𝑙𝑙𝑖𝑛𝑔 𝑖𝑛𝑑𝑒𝑥 =
𝑚2 − 𝑚1
𝑚1
× 100 Equation 8 
 
The tested units were subsequently left to dry at the RT for 24 hours and weighed again (m3) 
to see whether erosion had taken place during the swelling test. Erosion (%) represents the 
film dry matter that dissolved in the media and was calculated according to the Equation 9: 
 𝐸𝑟𝑜𝑠𝑖𝑜𝑛 (%) =  
𝑚1 − 𝑚3
𝑚1
× 100 Equation 9 
 
3.3.5.7. Surface pH of the films 
Three single-dose units of each formulation were placed in a beaker containing 5 mL of 
Milli-Q water and allowed to swell for 5 minutes. Surface pH was recorded for each film 
piece using a pH meter at room temperature. The mean value of the three parallels was 
calculated. 
 
3.3.5.8. Mucin interaction test 
The in vitro mucin-interaction test was performed with the Texture Analyzer with a setup 
modified from Hagesaether et al. (62). 50 µL of the 3% (w/w) porcine mucin was pipetted 
onto each side of two separate filter papers (1.25 cm × 1.25 cm). Each filter paper with an 
inert backing layer was taped to the Texture Analyzer – one to the lower, stationary part, and 
the other to the upper, moveable part as shown in the Figure 13. The tested unit (a film piece 
1 cm × 1 cm or half of the wafer with a diameter r=0.76 cm) was placed in between, and the 
upper part was manually moved downwards until the surfaces almost touched. The test was 
started by moving the upper probe towards the film or wafer until obtaining a contact 
between the two surfaces and applying a force of 2 N for 100 seconds. Afterwards, the upper 
probe was lifted with the speed of 0.01 mm/s. The force of detachment (Fmax, N) from the 
mucin-dispersion was recorded. Measurement was repeated 10 times for each film and 5 
times for each wafer formulation and was additionally performed with a PBS (instead of a 
mucin dispersion) as a reference to distinguish between general adhesion (test with mucin 
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dispersion) and nonspecific interactions (test with PBS), 10 times for the film and 5 times 
for the wafer formulations. The estimated mucin interaction was calculated by subtracting 
the unspecific adhesion from the general adhesion, measured in peak force generated during 
the probe return (Fmax). The mean value and SD were calculated. 
 
Figure 13: A schematic overview of the mucoadhesion test (63) 
 
3.3.5.9. In vitro dissolution test  
In vitro dissolution rate from the films and wafers was performed using with Transwell® 
setup with the pore size of 0.4 µm in 6-well plates as shown in the Figure 14. The setup 
consisted of an upper (donor) compartment and the lower (acceptor) compartment which 
were separated by the membrane (Transwell insert).  
 
Figure 14: Illustration of the in vitro dissolution setup in each well of the 6 well plate 
2.5 mL and 1.5 mL of the preheated saliva substitute (37 °C) were added to the lower and 
upper donor compartment, respectively. To maintain the sink conditions throughout the 
experiment, about 1/9 of the single-dose unit was used for each experiment. A tested sample 
with a predetermined weight (2.9–3.1 mg) was placed into the donor compartment. The plate 
was covered with plastic lid and incubated at 37 °C and 100 rpm. 500 μL aliquots were 
withdrawn from the acceptor compartment at pre-determined time intervals (15, 30, 45, 60, 
90, 120, 150, 180, 240 and 300 minutes) and replaced with 500 µL fresh preheated saliva 
substitute. The withdrawn samples were diluted with 500 μL of methanol to release the drug 
from the inclusion complexes. Prednisolone permeated through the membrane was 
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quantified by UV-VIS spectroscopy (λ=240 nm) using the calibration curve in the 
methanol:saliva substitute mixture. 3 parallels were repeated for each formulation. The 
cumulative amount of prednisolone released was plotted against time. Viscosan 
formulations, both films and wafers, were not tested due to time limitations. 
 
3.3.6. Biopharmaceutical characterization using HT29-MTX cell line 
Monolayers of mucus-producing HT29-MTX cells were used as a permeability model for 
studying the effect of mucus on the permeation of the drugs (64). The model membrane was 
a cell monolayer consisting of methotrexate treated HT29 cells (a human colon 
adenocarcinoma cell-line that spontaneously differentiates into monolayers of polarized 
enterocytes connected by tight junctions). 
 
3.3.6.1. Thawing the cells 
Cells (passage P22) stored in a cryogenic vial in the freezer (–80 °C) were transported into 
the laminar flow hood to start the thawing process. A small amount of warm fully 
supplemented DMEM growth media was added to the vials and the dispersion was manually 
pipetted to de-freeze the cells. They were transferred to the centrifuge tube with the media 
and centrifuged at 1000 rpm for 5 minutes to remove the cryoprotecting glycerol. The 
supernatant was removed and the cells in the pellet were resuspended in 10 mL of warm 
DMEM and seeded onto the cell flasks.  
 
3.3.6.2. Cell culturing 
The cells were seeded onto the cell culture flask with the surface area = 75 cm2 with the 
initial density of 2.4 × 104/cm2 and let to adhere and grow on the surface for 4 days before 
changing the media for the first time.  
They were routinely cultured in an incubator at 37 °C under a 5% CO2 atmosphere. The 
growth media was changed 3 times per week, i.e., approx. every second day. The cells were 
split at 60–80% confluency (approximately once per week) by trypsinization with trypsin-
EDTA. To achieve the desired seeding density (2.4 × 104/cm2), the cells were counted using 
a Countesse® cell counter prior to being resuspended in a fresh cell culture medium. Trypan 
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blue was used as an indicator of cell count and viability of the cells. The resuspended cells 
in DMEM were seeded onto a new flask with the same initial seeding density. Cells from 
passage P23 to P26 were used for experiments.  
 
3.3.6.3. Permeability test using HT29-MTX cell line 
The cells for permeability test were grown for 21 days on Transwell filter inserts with a 
0.4µm pore size and a growth area of 1.12 cm2 in 6-well plates to allow the cells to 
differentiate into mucus producing goblet cells. DMEM was changed three times weekly 
(approximately every second day). After 21 days, the mucus layer was formed on top of the 
cell-monolayer (Figure 15).  
The setup for the permeability test was similar as for the dissolution test (see 4.5.5), however, 
the Transwell inserts contained cell monolayers. 4 film formulations were tested (CM ace, 
CM lac, L lac, Visco) and the free drug dissolved in HBSS was used as a reference.  
 
Figure 15: A permeability test setup; adapted from (65) 
 
Prior to the experiments, the DMEM was removed from the upper and lower compartment 
and the cells was washed with HBSS. 2.5 mL of fresh, warm HBSS was added to the (lower) 
acceptor compartment. A film piece (approximately 3 mg; ca. 1/9 of the unit to ensure sink 
conditions) and 1.5 mL of HBSS were added to the upper, donor compartment. A reference 
(prednisolone dissolved in HBSS) was included as control. The plate was incubated at 37 °C 
and 100 rpm. Aliquots of 200 µL samples were collected at 30, 60, 120, 180 and 240 min 
from the acceptor compartment and replaced with 200 µL of HBSS after each withdrawal. 
Collected samples were pipetted into the wells of a 96-well plate. Prednisolone was 
quantified using a plate reader spectrophotometer at the wavelength λ=240 nm based on 
standards measured simultaneously in the 96-well plate. The concentration of drug at each 
31 
 
time point was plotted against time, and the slope of the linear part of the curve gives the 
drug permeated per time unit (dQ/dt). 3 parallels were repeated for each sample. 
The steady state flux (J) (Equation 10) and the apparent permeability coefficient (Papp) 
(Equation 11) were calculated for each experiment and the reported values represent the 
average of individually calculated Papp for each sample. dQ/dt represents the amount of drug 
permeated per time unit [mol/s] and A is the effective diffusion area. The apparent 
permeability coefficient (Papp) was calculated by normalizing the flux (J) over the total 
concentration of the drug (theoretical) in the apical side (C0). 
 𝐽 =  
𝑑𝑄
𝐴 𝑥 𝑑𝑡
 Equation 10 
 𝑝𝑎𝑝𝑝 =  
𝐽
𝐶0
 Equation 11 
 
3.3.6.4. Monolayer integrity 
Trans-epithelial electrical resistance (TEER) value was measured before, during and after 
the permeability experiments by placing one electrode to the donor compartment and the 
other to the acceptor compartment. The blank values (resistance of the Transwell inserts) 
were subtracted from the values obtained by the samples.  The TEER values were expressed 
in the standardised units (Ω × cm2). These should not drop significantly if the monolayer 
integrity is maintained after exposure to the formulations.  
 
3.3.6.5. Cytotoxicity 
After the permeability experiment with the formulations was concluded, the integrity of the 
cell monolayer after exposure to the various formulations was checked using the fluorescent 
paracellular marker 5(6)-carboxyflourescein (CF). After the withdrawal of the last sample, 
donor and acceptor chambers were washed with HBSS. 1.5 mL of 20 µM CF in HBSS was 
added to the donor compartment and 2.5 mL of HBSS to the acceptor compartment. The 
plate was incubated at 60 rpm and 37 °C for 60 minutes and the final TEER value was 
obtained. The amount of permeated CF in the acceptor chamber was determined using a 
plate reader at excitation wavelength of λ=485 nm and emission wavelength of λ=535 nm, 
providing the information about fluorescent intensity. It was expressed as the percentage of 
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CF applied that permeated the cell monolayer as shown in the Equation 12 and compared to 
the negative control (CF permeated through the membrane treated with free drug in HBSS).  
 
3.3.6.6. MTT assay using HT29-MTX cell line 
The MTT assay was conducted on HT29-MTX cells to assess the potential cytotoxicity of 
the film formulations and each of its components.  
Each single-dose unit of the films (CM ace, CM lac, M ace, M lac, L ace, L lac, Visco) was 
sterilized in a centrifuge tube in a laminar flow cabinet under the UV light for 30 minutes. 5 
mL of DMEM was added aseptically and the films were left in the media overnight to release 
the prednisolone from the formulations. The cytotoxicity test was performed on the solutions 
of the dissolved films.  
In addition to film formulations, each of the single components (chitosans CM, M, L, 
Viscosan, PN, HP-β-CD, glycerol, PEO, acetic acid and lactic acid) were tested separately. 
The components were prepared in DMEM to contain the same concentration as was 
theoretically present in each film sample, dissolved in 5 mL of DMEM. In addition to that, 
the single-component solutions were diluted with DMEM in 1:1 ratio. The final amounts of 
the tested samples are summarized in the Table IV. 
The cells were trypsinized according to the standard operation procedure for cell passaging, 
and seeded out in DMEM onto two sterile, clear plastic 96-well plates at a density of 1.5 × 
104 cells per well. They were incubated at 37 ° C in 5% CO2 for 24 hours to allow the cells 
to adhere to the bottom of the wells. Additionally, 6 wells in each plate were empty to serve 
as the background. 
After the cells had adhered to the bottom, cell culture medium was removed, and the cells 
were washed with HBSS. 200 µL of tested samples was added to each well along with the 
positive control (DMEM), negative control (1% Triton X) and background (empty wells). 6 
parallels were repeated for each formulation. The plates with solution of the films samples 
and the single components were left to incubate for 2 and 24 hours at 37 °C, respectively.  
 
 
𝐶𝐹 𝑝𝑒𝑟𝑚𝑒𝑎𝑡𝑒𝑑 (%) =  
𝑐 (𝐶𝐹)𝑎𝑐𝑐𝑒𝑝𝑡𝑜𝑟,60𝑚𝑖𝑛
𝑐 (𝐶𝐹)𝑑𝑜𝑛𝑜𝑟,0 𝑚𝑖𝑛 
× 100 Equation 12 
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Table IV: The tested samples and corresponding amounts on each 96-well plate 
PLATE 1 PLATE 2 PLATE 3 
Film 
formulation 










CM lac Chitosan M Chitosan M 
M ace Chitosan L Chitosan L 
M lac Viscosan Viscosan 
L ace Prednisolone 0.1 mg/mL Prednisolone 0.05 mg/mL 
L lac HP-β-CD 0.8 mg/mL HP-β-CD 0.4 mg/mL 
Visco Glycerol 0.1% V/V Glycerol 0.05% V/V 
  PEO 0.4 mg/mL PEO 0.2 g/mL 
  Acetic acid 1% V/V Acetic acid 0.5% V/V 
  Lactic acid 1% V/V Lactic acid 0.5% V/V 
 
After incubation, the tested samples were removed, and the cells were washed with HBSS. 
200 µL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reagent in 
DMEM (c=0.5 mg/mL) was added to each well and the plates were incubated for another 3 
hours at 37 °C. The MTT reagent was removed and 200 µL of dimethyl sulfoxide (DMSO) 
was added. The plate was shaken at 100 rpm for 15 minutes. In the process, the yellow MTT 
reagent is reduced to purple formazan in cells that are viable and living. The amount of 
formazan was quantified spectrophotometrically by fluorimetry (λ=570nm and λ=630nm 
corresponding to emission and excitation wavelengths of formazan, respectively). 
Cell viability was calculated according to the Equation 13:  
𝐶𝑒𝑙𝑙 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (%) =  
𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 𝑣𝑎𝑙𝑢𝑒 − 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 − 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
× 100 Equation 13 
 
A paired, two-sided student t-test was performed to distinguish the differences in the cell 
viability in respect to the formulation types, separate components, and the effect of the 
component concentration on the viability of the cells. A significant difference was 
considered p value p<0.05.  
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4. RESULTS AND DISCUSSION 
4.1. PHASE SOLUBILITY OF PREDNISOLONE IN HP-Β-CD 
The solubility of prednisolone is plotted against HP-β-CD concentration in Figure 16. The 
intrinsic solubility of prednisolone in distilled water was determined to be So=189 ± 3 mg/L 
(0.524 ± 0.009 mmol/L) at 23 °C and increased linearly with the increasing HP-β-CD 
concentration. The intrinsic solubility was slightly lower than the observations in the 
literature (223 mg/mL at 25 °C) (51) which may be due to a lower temperature or any 
impurities present in the samples. Prednisolone and HP-β-CD are complexed in a 1:2 molar 
stoichiometry with the CE=0.880 and Ks=5.2. The calculated molar stoichiometry was used 
to deliver prednisolone in the form of inclusion complexes with HP-β-CD in films and 
wafers.  
 
Figure 16: Phase solubility of prednisolone in HP-β-CD- containing the aqueous solution 
Similarly, the solubility of the drug was determined in other selected media with and without 
HP-β-CD present and in a molar stoichiometry obtained from the experiment in water (Table 
V).  
The solubility in saliva substitute, 1% V/V acetic acid and 1% V/V lactic acid, respectively, 
gave corresponding results to the water suggesting that the solvent and its pH do not affect 
the drug solubility. The result complies well with the literature stating that PN is a neutral 
molecule without acidic or basic functional groups (51). This also implies that the stability 
of the inclusion complex is similar for the different solvents used in the formulation process 
as well as the biologically relevant saliva substitute used in drug release experiments. 
 




















Table V: Prednisolone solubility in selected media with and without HP-β-CD 
Media Solubility of 
prednisolone [mmol/L] 
no CD present 
Solubility of 
prednisolone [mmol/L] 
5.93 mM CD 
Saliva substitute (pH=6.80) 0.497 ± 0.002 2.661 ± 0.030 
Acetic acid (pH=2.76) 0.560 ± 0.006 2.632 ± 0.054 
Lactic acid (pH=1.95) 0.524 ± 0.010 2.334 ± 0.041 
 
In addition to the increased solubility of poorly water-soluble drugs, the formation of 
inclusion complexes may contribute to the taste masking of bitter-tasting drugs, such as 
prednisolone. The entrapped drug cannot act at the taste buds receptors as opposed to the 
free drug, which may result in a more appealing taste of the dosage form (66).  
 
4.2. FILM PREPARATION 
4.2.1. Film formulation optimization 
The main stages of the film formulation optimization are summarized in Figure 11. 
The initial step in the optimization process was to determine the film formulation. Firstly, 
the optimal ratio between chitosan and poly(ethylene oxide) was determined using a total 
polymer concentration of 2% (w/w). The films with the chitosan/PEO ratio= 1/1 were 
slightly opaque, stiff, and brittle. The use of the 9/1 ratio resulted in more transparent films. 
Due to the more promising results obtained by DSC (see 4.2.2), the 9/1 ratio was used in 
future development. Films tended to break and, therefore, the further addition of a plasticizer 
was considered. 
The second step in the development stage was the addition of glycerol as an additional 
plasticizer to obtain higher flexibility. A total glycerol concentration of 4% and 2% m/m was 
too high resulting in the sticking of the films to the fingers. An optimal balance between 
flexibility and easiness to handle was achieved with the addition of 1% m/m of glycerol to 
the wet film formulation. Therefore, the basic composition for the preparation of films and 
wafers was the chitosan/PEO ratio of 1/1 (total polymer concentration = 2% w/w) and 1% 
m/m glycerol.  
The third step was the optimization of the film or wafer producing technique, for example, 
casting the film on a completely flat surface and checking for any anomalies, such as 
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entrapped air bubbles in the final product. Films with chitosan M (with both acids present) 
appeared to have had several air bubbles incorporated. Therefore, the solution was later on 
sonicated for 15 minutes before solvent casting. The additional step improved the overall 
texture of the films. 
By freeze-drying of different amounts of the wet formulations in the 24 well plates, 0.60 g 
of film solution was considered the most appropriate reaching the wafer thickness of about 
half a centimeter.  
The final step in the optimization process was the production of the final formulations. 
100 mg of prednisolone along with the corresponding amount of HP-β-CD (800 mg) was 
added to 100 g of polymeric solutions to obtain 600 micrograms of the drug per single-dose 
unit. These formulations were subsequently tested and will be further discussed in the 
following chapters.  
 
4.2.2. DSC analysis 
The DSC analysis was conducted on the blank films (i.e. containing the only polymer in the 
1% V/V acetic acid and 1% V/V lactic acid) to evaluate the behavior of the polymers as a 
function of temperature.  
DSC thermogram for the formulations containing chitosan/PEO = 1/1 ratio showed an 
endothermic peak at about 60 °C which corresponds to the melting point of PEO. A wide 
peak occurring at 90–160 °C may be a result of the evaporation of the bound water. The 
maximal tested temperature reached 180 °C which is not high enough to cause 
decomposition of the chitosan. The cooling process shows the exothermic peak at 40 °C with 
a similar peak area to the endothermic melting peak corresponding to the recrystallization of 
the PEO (Figure 17).  
It may be assumed that the films with such a composition appeared opaque and brittle due 
to the small polymer crystals present in the product. By lowering the total amount of PEO in 
the final product, films were expected to appear more flexible and transparent.  
The DSC thermogram of the chitosan/PEO = 9/1 ratio had a similar endothermic peak at 60 
°C and a wide peak at 70–100 °C during heating as the previously tested sample. 
Nevertheless, the exothermic peak was not present during the cooling until reaching –25 °C 
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(Figure 18) suggesting that the PEO recrystallization does not occur at room temperature 
(67).  
 
Figure 17: A DSC thermogram (chitosan M/PEO = 1/1 in 1% V/V acetic acid) 
 
 
Figure 18: A DSC thermogram (chitosan M/PEO = 9/1 ratio in 1% V/V acetic acid) 
 
The DSC analysis was not performed on the final products. Nevertheless, this information 
on the final product would provide more accurate information on the stability of the 




4.2.3. The viscosity of the wet formulations  
Since buccal films and wafers are made from relatively viscous solutions, it was important 
to consider their rheological factors, especially viscosity in the solvent casting process.  
Viscosities of the tested film solutions are presented in the Table VI and compared to the 
viscosity information provided by the manufacturers for 1% chitosan in 1% acetic acid 
solution. The measured viscosity ranges between 542 and 38243 mPa × s and was highly 
dependent on the type of chitosan and solvent used. Polymer solutions containing lower Mw 
chitosans (CM and M) had more comparable viscosity in the two solvents while the high 
Mw chitosan L was significantly more viscous when dissolved in lactic acid as opposed to 
acetic acid. To obtain information regarding the reasons for viscosity difference, additional 
rheological studies should be executed. Nevertheless, it may be assumed that this chitosan 
forms stronger intermolecular bonds when dissolved in lactic acid at a lower pH. The highest 
viscosity was noted for the Viscosan film solution. The ranking order was similar as for the 
chitosan information from the manufacturer, except for Viscosan, which was much higher. 
Table VI: Viscosity of the film solutions (n=3) 
Chitosan type Solvent Viscosity ± SD (mPa × s) 
Viscosity of 1% chitosan * 
(mPa × s) 
Chitosan CM Acetic acid 542 ± 23 
134 
Chitosan CM Lactic acid 627 ± 6 
Chitosan M Acetic acid 2349 ± 34 
488 
Chitosan M Lactic acid 2357 ± 84 
Chitosan L Acetic acid 7377 ± 192 
1470 
Chitosan L Lactic acid 13360 ± 850 
Viscosan Water 38243 ± 2245 635 
*Information obtained from the manufacturers 
 
The observed viscosities for the small-scale production in a petri dish in the literature differ 
over a wide range from 1.7 to 1843 mPa × s. A low viscosity was described to lead to 
variations in film thickness at different sites potentially and therefore to poor drug 
uniformity. On the other hand, a high viscosity may interfere with the free flow of the 
solution, increase the probability for the air bubbles entrapment, and thus prolong the 
production time which is to be avoided on a large-scale production (18).  
39 
 
Despite the high viscosities obtained, the film solutions were cast easily except for the 
chitosan L in lactic acid and Viscosan. These could potentially contain a lower total polymer 
concentration to facilitate the large-scale production process. 
 
4.2.4. Visual and sensory inspection of the films and wafers 
The produced films were flexible, easy to handle, and did not stick to the skin when touched 
by the fingers. Their surface was transparent, smooth, and homogeneous. They meet the 
prerequisites for the appearance as it is highly recommended to develop film products that 
would have an appealingly smooth, soft, and air bubble-free surface (18). 
Wafers were white, spongy, tack-free, and easy to handle and met the requirements for 
flexibility, elasticity, and softness (68). An example of both the products is shown in Figure 
19.  
The use of acetic acid as solvent resulted in a strong odor (similar to vinegar) of the products, 
which could appeal less pleasant and, therefore, possibly reduce the patients’ compliance, 
especially in children. From this perspective, odorless films containing lactic acid or water 
may be preferred for buccal administration.  
The size of the appropriate dosage form is limited by the space provided for the 
administration at the site of drug application. Orodispersible films with a 2 cm × 2 cm square 
surface and a thickness of 100 µm were considered an adequate size for the oromucosal drug 
delivery in the literature (18). Therefore, we were aiming for the same surface area and a 
low thickness to meet the children’s needs. There was no information provided about the 
appropriate size for wafers in the literature. However, the size obtained from each well in a 
24-well plate was estimated to be an acceptable size for the delivery to the buccal mucosa. 
   
Figure 19: An example of a film piece (left) and a wafer (right) (CM in lactic acid) 
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4.3. PHYSICAL ATTRIBUTES  
The attributes of the film and wafers characteristics are summarized in Table VII.  









± SD (µg) 
Surface pH ± 
SD  
F1 CM Ace 25.3 ± 4.5 52 ± 14 µm 475 ± 66 4.30 ± 0.08 
F2 CM Lac 34.4 ± 3.1 65 ± 15 µm 470 ± 46 3.60 ± 0.12 
F3 M Ace 24.3 ± 3.6 53 ± 12 µm 540 ± 39 4.29 ± 0.11 
F4 M Lac 29.9 ± 4.0 60 ± 14 µm 503 ± 47 3.81 ± 0.03 
F5 L Ace 24.3 ± 4.8 51 ± 10 µm 531 ± 64 4.27 ± 0.11 
F6 L Lac 36.0 ± 8.1 58 ± 12 µm 449 ± 129 3.55 ± 0.06 
F7 Viscosan 33.1 ± 3.9 47 ± 7 µm 604 ± 56 5.85 ± 0.11 
F8 FD CM Ace 26.4 ± 1.2 4.3 ± 0.2 mm 397 ± 56 4.65 ± 0.11 
F9 FD CM Lac 29.3 ± 0.7 4.2 ± 0.3 mm 391 ± 44 3.89 ± 0.14 
F10 FD M Ace 26.1 ± 0.5 3.9 ± 0.1 mm 391 ± 63 4.50 ± 0.06 
F11 FD M Lac 29.3 ± 1.4 4.1 ± 0.1 mm 493 ± 71 3.80 ± 0.06 
F12 FD L Ace 25.0 ± 0.7 4.1 ± 0.1 mm 496 ± 39 4.49 ± 0.04 
F13 FD L Lac 29.1 ± 0.7 4.0 ± 0.2 mm 504 ± 51 3.69 ± 0.09 
F14 FD Viscosan 24.0 ± 1.4 4.1 ± 0.2 mm N.A.* N.A.* 
*N. A: result not obtained 
4.3.1. Uniformity of mass, drug content and thickness 
Films  
The mass of the films spanned from 20 to 44 milligrams per film piece, most commonly 
weighing 25–30 milligrams. The produced films did not comply with the criteria of Ph. Eur. 
for uniformity of mass for single-dose preparations. The variance between the samples was 
high, possibly due to the surface used for solvent casting. It was visible that some edges had 
a higher film thickness compared to the others. Therefore, outer edges should be excluded 
from the measurement. By drying the solutions on a completely flat surface, more even 
distribution could be achieved. 
The films’ thickness ranged between 40 and 80 micrometers with an average of 55 
micrometers. These values may be considered adequate in the sense of application as they 
are intended to be placed in the mouth and should, therefore, not be too thick to cause an 
unpleasant effect or pain. Ideally, the oral film should exhibit a thickness between 50 and 
1000 μm (36). The lower thickness results increase the frangibleness of the films while the 
higher values were reported to produce rough surfaces due to an increase in internal tensions 
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(69). The production was aimed towards the lower limit to fulfill the pediatric patients’ needs 
and make the administration process more feasible. 
Dosage forms must contain a precise drug load to ensure dosing accuracy (18). The films 
showed a relatively high deviation in prednisolone content between the formulations 
spanning over a wide range (320 to 660 µg) with an average of approximately 500 
micrograms per film piece and do not comply with the Ph. Eur. requirements for the 
uniformity of drug content for single-dose preparations. The drug loading was lower than 
the theoretical content (600 µg) which may be due to photodegradation of prednisolone or 
the fact that the drug was not yet fully released from the cyclodextrin complexes. The 
samples with a lower weight may have also contributed to the lower drug content as the two 
factors correlate closely. Additionally, the calibration curve could be investigated to find 
whether the background polymers provide an additional absorbance that is not pronounced 
in the tested samples. By ensuring a high mass uniformity, the uniformity of drug loading 
between the films could also have been improved. 
 
Wafers 
Wafers’ mass ranged between 26 and 30 milligrams with a low deviation between samples. 
The criteria of Ph. Eur. for uniformity of mass for tablets with a low dose was fulfilled for 
all the wafer formulations. Homogeneity was obtained more easily since a precise amount 
of polymer was weighed in each well resulting in an even mass distribution between wafers.  
The thickness of the wafers was very uniform (about 4.0 mm). However, it should be 
mentioned that they were extremely spongy and prone to physical deformation and it was, 
therefore, difficult to measure the initial thickness. By applying pressure on the wafers, the 
thickness decreased significantly. Since we were interested in the initial stage occurring 
during administration to the buccal mucosa, the initial values were recorded. 
Tested wafers contained on average 400 to 500 µg of prednisolone, which is, similarly as in 
the films, i.e. lower than the theoretical value. It may be assumed that the drug was not 
completely released from the cyclodextrins. A longer time of sonification or the use of a 




4.3.2. Surface pH  
The observed surface pH results are presented in Table VII. Films and wafers with acetic 
acid possessed a pH of 4.27–4.65 while lactic acid formulations had a slightly lower pH 
(3.55–3.89). Viscosan film formulations are the closest to neutral with an average pH of 
5.85. It is known that alkaline (pH>8) or acidic (pH<4) pH affects the mouth 
microenvironment and may lead to local irritation or discomfort at the interface between the 
mucosal site and dosage forms (18,23). Hence, it is preferable to keep the pH of the product 
as close to the physiological pH as possible because oromucosal films adhere to the surface 
for a longer time. In this case, acetic acid or water is advantageous with a more neutral pH 
compared to the formulations containing lactic acid. In the further formulation development, 
the minimization of the amount of lactic acid for dissolving the polymer may be considered 
to elevate the pH of the final product.  
 
4.4. MECHANICAL PROPERTIES 
4.4.1. Puncture strength 
Puncture strength represents the maximum strength the film can withstand before breaking 
while elongation expresses the ability of a film to stretch (67). The results considering the 
tensile strength of films are presented in Figure 20. The average tensile strength values of 
produced films range from 6 to 14 N/mm2 and differ among the formulations.  
 



























The film strength should be high enough to be peeled from the solvent casting surface and 
have sufficient flexibility to avoid breaking or rupture but not too high due to the possibility 
of film deformation during the packaging or cutting into single-dose units (19).  
Among the tested samples, the presence of acetic acid resulted in a higher tensile strength 
of the films than when lactic acid was used. The specific properties of the polymeric aqueous 
solutions, such as ionic strength, pH, and degree of dissociation, affect the hydration, 
relaxation, and intermolecular arrangement of chitosan in an aqueous solution. 
Consequently, the physical properties of the films may also be altered. It was shown that 
chitosan molecules form dimers in acetic acid solution and increase the intermolecular 
interaction as opposed to other acids including lactic. Nevertheless, a wide range of values 
for tensile strength of similar films have been reported in the literature – a comparison 
between the chitosan films made with acetic and lactic acid achieve the values from about 
32 to 165 N/mm2 and 2 to 74 N/mm2 with lactic acid (70,71). 
Additionally, the effect of chitosan Mw was pronounced in the formulations with acetic acid 
showing increased mechanical strength in correlation to the increasing molecular weight of 
chitosan. The statistical difference between the three samples was significant (p<0.05). The 
tensile strength of chitosan films is known to increase with the increasing molecular weight 
of chitosan due to the formation of hydrogen bonds between hydrophilic (-NH2 and -OH) 
groups in chitosan and forming of an entanglement three-dimensional network (71,72). 
However, this effect was not observed in the films with lactic acid possessing no statistical 
difference between the tested film samples. The reason for the discrepancy may be in the 
different thicknesses of the films which could affect the puncture strength – by obtaining 
this information and testing the samples with a comparable thickness, the variance could be 
diminished, and more accurate conclusions could be obtained.  
Viscosan films had comparable strength to medium and high Mw chitosan with lactic acid 
and a higher to the other formulations (p<0.05). This may be a consequence of its evenly 
distributed deacetylated groups that maximize the surface available to form chemical bonds. 
Since the estimation of the film strength suitability lacks the requirements to fulfill the 
criteria, a comparison to the commercially available products may estimate the mechanical 
properties in respect to the approved products. Using a similar setup, the values for marketed 
orodispersible films spanned between 0.08 and 0.36 N/mm2 (37). Since the formulations 
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produced in the research reach values higher than 6 N/mm2, it may be concluded that their 
strength is appropriate for further development. 
The test setup was not suitable for the wafers since their diameter was too small to be 
fastened in the rig. Therefore, the mechanical test was not performed for the wafers. 
However, the handling and sensory analyses of the wafers indicated that the spongy structure 
characteristic for the lyophilised products would have lower mechanical strength and 
flexibility as compared to the films. 
 
4.4.2. Elongation to break 
The elongation to break is an indicator of the extensibility of the films. The results from the 
experiment are represented in Figure 21. Generally, the values range between an average of 
48 and 71%, except for the Viscosan films, which have a significantly lower elasticity (24%) 
than the rest (p<0.05).  
 
Figure 21: Percent of elongation of films (%) (n=5) 
A trend of the higher elongation percent is observed with the decreasing Mw of chitosan and 
was significant when comparing the three tested samples containing acetic acid (p<0.05) but 
was not observed when lactic acid was used. 
Generally, films made with lactic acid as a solvent have better elasticity than the ones with 
acetic acid suggesting a contribution to the plasticizing effect of the lactic acid incorporated 
into films. Reported values for chitosan film elastic properties in literature were between 




























to break to the tensile strength, the correlation between the tensile strength and elongation to 
break seems to be inversely related. A more pronounced entanglement between the 
polymeric chains increases the strength but also leads to a more rigid structure of the chains 
(71).  
To estimate the elasticity in respect to the marketed film products, the results were compared 
to the observations in the literature – the obtained values spanned between 4% and 9%. As 
the elongation to break of our produced formulations reached values higher than 24%, their 
elastic properties may be considered adequate (37). 
The use of a plasticizer may additionally affect the final product elasticity and has previously 
shown to play a role in the elastic properties of films (71). Moreover, the results may be 
impaired by the residential water in the product and varying relative air humidity. Therefore, 
the storage conditions must be evaluated and controlled throughout the production and 
storage.  
 
4.5. PHYSICOCHEMICAL AND BIOPHARMACEUTICAL 
CHARACTERIZATION 
4.5.1. Disintegration test 
There is no disintegration test specified in the European pharmacopeia for mucoadhesive 
buccal films nor oral film formulations. Nevertheless, mucoadhesive films and wafers are 
not expected to disintegrate as the physiological pH because they are intended to remain in 
close contact with the buccal mucosa for a longer period. The experiment showed that neither 
of the films or wafers disintegrated during the 3 hours of being soaked and shaken in saliva 
substitute at 37 °C. After the experiment, the cohesive matrix was still visible. This result 
was expected and is advantageous because it would enable the drug to be released from the 
dosage forms in a controlled manner over a longer period.  
 
4.5.2. Swelling 
Hydration and swelling are the fundamental requirements for biological adhesion and are 
known to affect the drug release from the delivery system (30). Ideally, the polymer would 
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swell to a certain degree but not to the point where it may cause discomfort or pain on the 
oral mucosa due to an unpleasant and unfamiliar feeling in the mouth.  
The swelling behavior of the films and wafers is plotted as a mean of three parallels along 
with the standard deviation in Figure 22 and Figure 23, respectively. 
 
4.5.2.1.Swelling of the polymers in the films 
The lower molecular weight of the chitosan resulted in increased swelling of the film which 
is apparent from the same trend observed when both the acids were used. This observation 
can be related to the higher flexibility chains within the polymer with a lower Mw and 
consequently a larger number of polar groups that are available for interaction with the water 
molecules. 
 
Figure 22: Swelling index of the films 
Films produced with lactic acid as a solvent showed higher swelling index cases than the 
corresponding formulations made with acetic acid. Generally, the observed swelling index 
is 3–4 times higher. Since the dissolved lactic acid films are more acidic than acetic acid 
films (see 4.3.2), the polar amino groups in chitosan are more protonated in an aqueous 
media – a repulsion between those may lead to enhancement in swelling capacity (73). 
Viscosan film produced with water as a solvent has a relatively high swelling degree in 
respect to the other formulations which may be attributed to its structure. Since the 
deacetylation does not follow a blockwise pattern as other types of chitosan do, an even 
distribution enables the water molecules to form a larger number of hydrogen bonds and 


























4.5.2.2.Swelling of the polymers in the wafers 
The produced wafers increase their weight dramatically in the contact with the aqueous 
solution – due to their highly porous structure, water can interpenetrate the dosage form and 
interact with a large number of hydrophilic groups in chitosan molecules.  
Similarly, as for the films, lactic acid provides wafers with a larger swelling capacity as well 
as does the use of low molecular weight chitosan. The effect of chitosan molecular weight 
is less pronounced in the films produced with acetic acid. The differences may be less 
pronounced among the different formulations because hydration of the polymers occurs 
mainly due to its ability to retain the water inside its structure itself and is less dependent on 
the type of chitosan or the solvent. 
 
Figure 23: Swelling index of the wafers 
 
From the administration perspective, the swelling of the polymers should not be too 
extensive as this may result in pain and/or discomfort in the oral cavity.  
The low molecular weight chitosan formulations containing lactic acid represent a huge 
volume increase (Figure 24) which may be undesirable for the administration of buccal 
films, especially to children. The other formulations, including films and wafers, were 























Figure 24: Swelling of the wafers containing CM chitosan produced with lactic acid (above) and 
acetic acid (below) 
 
4.5.3. Erosion of the films and wafers 
The erosion of tested formulations is presented in Figure 25. All the films showed a similar 
degree of erosion after 5 minutes in saliva substitute – about 40% of the initial mass was lost 
when the film was dried due to the disentanglement of the loosely bound polymer molecules. 
The polymer erosion was significantly lower in wafers spanning between 7% and 22% of 
the dry mass. Possibly, the wafers were not completely dry after 24 hours resulting in a lower 
apparent erosion. By re-weighing them after another day or two, more accurate conclusions 
could be obtained. 
 
Figure 25: Erosion of the films and wafers after 5 minutes in saliva substitute (%) (n=3) 
 
From the drug administration perspective, the eroded part would be potentially swallowed 
by the patient and absorbed throughout the gastrointestinal tract as opposed to the main, 

















Acetic acid Lactic acid water
49 
 
considering a high absorption (80–100%) of prednisolone via the gastrointestinal tract (51). 
On the other hand, erosion is less suitable for the treatment of local conditions in the oral 
cavity as a major part of the drug would be washed from the oral cavity. 
 
4.5.4. Mucin interaction test 
The adhesive forces between the formulation and a hydrated surface were investigated to 
gain information about mucoadhesion. Figure 26 represents the peak force versus mucin 
(general adhesion) and buffer (unspecific adhesion) for each formulation. Estimated mucin 
interaction is the subtracted value between the two (=general adhesion–unspecific 
adhesion). Apparently, the general adhesion is higher than the unspecific adhesion 
suggesting the interaction of chitosan with negatively charged functional groups in mucins.  
 
Figure 26: Estimated mucin interaction for cast films (left) and wafers (right) 
 
Unspecific adhesion refers to the adhesion to the wet surface regardless of its composition. 
These values are generally higher for wafers than for films. It was shown that the use of a 
lower Mw chitosan and lactic acid contributes to a higher unspecific adhesion in the films. 
Keeping in mind the swelling behavior of the formulations, the results indicate that swelling 
is advantageous as the hydration of the polymer leads to a non-specific adherence to the 
surface facilitating the rapid mucoadhesion to the absorptive epithelia. In this context, 
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wafer to interact with mucosa. This effect is less pronounced in the wafers where the 
unspecific adhesion is similar regardless of the composition. Similar results were observed 
for the swelling capacity of the wafers where the porous structure of the formulations 
contributes the most to the water-uptake ability. 
Estimated mucin interaction is the specific adhesion that excludes the adhesion to the buffer 
and is influenced by the capability of the polymer to form chemical bonds (e.g. electrostatic 
interactions, hydrogen bonds) with the structures in mucin as well as engage in 
entanglements formation (74).  
The formulations containing low Mw chitosan (CM) are estimated to interact better with the 
mucin than the medium and high Mw chitosan. The highest specific interaction is achieved 
by CM chitosan in lactic acid in both films and wafers. To achieve a desirable adhesion to 
the mucosal surface, the most appropriate formulations seem to be films with chitosan CM 
(both acids), M (lactic acid), and Viscosan (water).  
Despite high general adhesion results observed in all the wafers, the effect of the buffer 
interaction is very high and does not provide as much of an interaction with mucins. The 
inter-individual changes are less expressed. Nevertheless, a high proportion of the interaction 
is specific and, therefore, should be considered for future development. Viscosan 
formulation was not tested for the wafers because of the time limitations. 
 
4.5.5. Dissolution test 
The following figures represent the cumulative amount of release prednisolone from all films 
and wafers, except for the Viscosan formulations which were not tested because of time 
limitations. It must be noted that a smaller piece of film or wafer, about 1/9, was tested and, 
therefore, the theoretical content of prednisolone was correspondingly lower (approximately 
70 µg).  
4.5.5.1.Films 
The release profile of prednisolone from films is presented in Figure 27 and Figure 28.  
The cumulative amount of released prednisolone was almost identical for all the films up to 
the first 30 minutes of the test when about half of the prednisolone was released. This 
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probably corresponds to the part of the drug load that is associated with the outer surface of 
the formulation and is easily dissolved.  
 
Figure 27: Prednisolone release profile from the cast films with acetic acid (n=3) 
 
Figure 28: Prednisolone release profile from the cast films with lactic acid (n=3) 
Both low molecular weight (CM) chitosan formulations seem to provide the faster release 
as opposed to the higher molecular weight chitosan with a typical shape of release from a 
hydrogel. The release from the formulation prepared with lactic acid is somewhat slower 
than that of the one from acetic acid, which may reflect the swelling of the polymers which 
was also found to be higher in lactic acid as compared to acetic acid.  
The release curves for films based on M and L chitosan form a plateau between 30–60 min 
before the release slowly increases again. It might be hypothesized that at this point the films 
































































The diffusion barrier depends on the polymer type as well as the acid used in the preparation 
(i.e., pH of the hydrogel) since the swelling of the polymer is pH-dependent. 
At the end of the experiment, the drug was completely released from the films taking the 
theoretical drug loading into account. On the other hand, not all the curves reached a plateau 
at that point yet. Therefore, it is possible that the dosage forms had a higher loading than 
anticipated or that there was an additional substance present in the product as a background 
that has interfered with the absorbance. For the quantification of that, more precise methods, 
such as high-performance liquid chromatography, could be used. 
 
4.5.5.2.Wafers 
The release profile of prednisolone from the wafers is presented in Figure 29 and Figure 30.  
The release profiles from the wafers follow a very similar rate as for the films during the 
first 30 minutes. For these formulations, however, the continuation of the release curves is 
only slightly affected by the type of chitosan and the solvent. The release was found to be 
slowest from the high Mw chitosan L for both solvents and slightly slower when lactic acid 
is used as the solvent for film preparation. This corresponds to the degree of swelling which 
is higher in lactic acid as compared to acetic acid. The effect of molecular weight is less 
pronounced for the wafers which might be explained by their structure. The gel is frozen in 
a hydrated state and the 3D network is preserved as the water is removed by sublimation 
leaving the dry gel with a highly porous structure that can easily and quickly be hydrated. 
The minor differences between the polymers with different molecular weights indicate that 
the pores of the sponge are in the same order of magnitude and that the chains of the polymer 
are not freely moving until the drug has diffused out.  
The test was performed for 5.5 hours in total. Half of the drug was released after 
approximately 45 minutes and the complete dissociation occurred after 5 hours. Similarly, 
as for the films, most of the prednisolone appeared to be released from the formulations (65–
75 µg) in respect to its theoretical content (70 µg) at the end of the experiment. However, 
the curve still did not form the plateau. Therefore, additional experiments should be carried 
out to find the reason for the discrepancy between the theoretical drug loading and the 




Figure 29: Prednisolone release profile from the wafers with acetic acid (n=3) 
 
 
Figure 30: Prednisolone release profile from the wafers with lactic acid (n=3) 
 
4.5.5.3.Limitations and further perspectives 
Despite the discrepancies between some of the dissolution profiles as opposed to the 
theoretical calculations, the prednisolone release seemed to reflect the composition of the 
tested products. A sustained release profile was achieved using all 12 delivery systems. 
Therefore, it may be assumed that films and wafers would be able to release the drug over a 
prolonged period in a controlled matter. By incorporation of the drug into the films, the 































































playing a significant role in the wafers – in this case, the other parameters would be 
considered more important when deciding on an appropriate formulation.  
 
4.6. CHARACTERIZATION USING HT29-MTX CELL LINE 
Mucus-producing HT29 (HT29-MTX) cell line was used as a part of the in vitro evaluation. 
This a completely differentiated goblet cell line deriving from the HT29 human colon 
carcinoma cell line (75). Since it is immortal and grows mucus on top of the monolayers, it 
is widely used to assess the permeability, mucoadhesion, and biocompatibility of various 
substances through the epithelial surface (76). 
 
4.6.1. Permeability of prednisolone from the films and wafers 
Table VIII shows the calculated flux (J) and apparent permeability coefficient (Papp) for 
prednisolone from the tested formulations.  
Table VIII: The calculated flux (J), apparent permeability constants (Papp) of prednisolone through 
the cells and CF permeability 
 
J (µg/cm2 × h) Papp [10 -6 cm/s] CF permeability (%) 
CM ace 0.417 ± 0.059 3.41 ± 0.41 4.12 ± 0.69 
CM lac 0.561 ± 0.088 3.53 ± 0.65 2.53 ± 1.22 
L Lac 0.522 ± 0.054 3.26 ± 0.30 1.30 ± 0.31 
Viscosan 0.625 ± 0.072 3.20 ± 0.20 1.21 ± 0.09 
Free drug 0.602 ± 0.093 4.46 ± 0.78 1.50 ± 0.13 
 
The permeability of prednisolone from the film formulations was lower than from the 
reference (free drug dissolved in HBSS) suggesting a slower release of the drug from the 
inclusion complexes before reaching a free solute form to achieve transepithelial permeation. 
The Papp value differences between the four tested formulations were not significant and are 
spanned between 3.20 and 3.53 × 10-6 cm/s as opposed to the free drug (4.46 × 10-6 cm/s). 
This is exactly what the incorporation of the drug into the mucoadhesive drug delivery 
platforms is supposed to achieve enabling the controlled and sustained release over a 
prolonged period.  
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Nevertheless, the results cannot be directly transferred to in vivo drug permeation because 
the biological conditions, including the pH, ionic strength, pore size, and viscoelasticity, 
influence the drug delivery (8). 
Literature states a permeability coefficient of 2–4.5 × 10-6 cm/s for prednisolone in Caco-2 
cells which is comparable to the obtained data (77). The expected Papp values were slightly 
lower because the Caco-2 cells do not contain mucus. Hence, the mucus layer on the top of 
HT29-MTX does not seem to affect the permeability of the drug through the membrane. 
Although the mechanism of permeation is not fully explained, it may be assumed that 
steroids influence the fluidity of biological membranes. Cholesterol is a common constituent 
of the biological membrane – thus, the presence of the steroid scaffold may be advantageous, 
resulting in a high permeation of the steroid molecules as is prednisolone (77). 
Based on the results, it may be suggested that the drug would be readily absorbed from the 
produced drug delivery systems. According to the European Medicines Agency, complete 
absorption (≥85%) is generally related to high permeability (78).  
 
4.6.2. Toxicity of the formulations 
4.6.2.1. 5(6)-carboxyfluorescein permeability 
CF is a fluorescent paracellular marker that can indirectly estimate the sample toxicity on 
the cells as increased permeability reflects the weakening of the tight junctions and loss of 
the cell monolayer integrity. Consequently, a higher amount of CF permeates through the 
cell membrane (76). Ideally, the CF permeability after treatment with the film formulations 
would be close to the referential value (free drug in HBSS). It was comparable to the 
reference when testing CM lac, L lac, and Viscosan films and similar to the observations in 
the literature (76) (Table VIII). A slightly higher value (4.12%) was obtained for CM ace 
films. This might be explained by the accidental manual disruption of the cell monolayer 
during TEER measurement with a volt/ohm meter since the expected biocompatibility of 
this formulation was not different than others. Based on these results, the biocompatibility 




4.6.2.2. Transepithelial electrical resistance (TEER) 
Transepithelial electrical resistance (TEER) of different formulations was conducted on 
HT29-MTX cells before and during the permeability experiment with the 4 film samples 
which were studied with the free drug solution as a reference. The result usually reflects the 
ion permeability and should be maintained as constant as long as the integrity of the 
monolayer is intact. The TEER values throughout the whole experiment are presented in the 
Figure 31. They ranged on average from 170 to 180 Ω × cm2 when the blank values 
(Transwell inserts) were subtracted and were comparable to the standard values observed 
from the literature (125–220 Ω × cm2) (79).  
The TEER values did not decrease significantly during the incubation with the test samples, 
except for the formulation with CM chitosan in lactic acid. Nevertheless, the standard 
deviation is also relatively high suggesting that cell monolayer might have been disrupted in 
one of the wells throughout the experiment. As the TEER value increases again at the end 
of the experiment. No conclusions on the toxicity of this formulation can be concluded and 
additional research should be carried out. 
 
Figure 31: TEER values during the experiment for various samples 
 
4.6.3. Cell viability (MTT) test 
MTT assay is a colorimetric cell viability test that was conducted to estimate the toxic effect 
of the films and each of the film components on the cell line. The cellular oxidoreductase 
enzymes can reduce the MTT reagent to formazan reflecting the metabolic activity of the 






















metabolic activity of the cells can be elevated upon stress (causing higher absorbance values) 
or reduced because of cell death (lower absorbance values) (64). A percentage of the cells 
surviving the incubation with the samples can indicate whether formulation could impact the 
cell viability and affect the drug delivery to the buccal mucosa. According to the guidelines 
from the regulatory authorities, toxicity is considered significant if more than a 30% 
reduction in the cell metabolic activity has occurred (64). The MTT test results from the cells 
after exposure to film formulations are presented in Figure 32. 
 
Figure 32: Cell viability (%) after exposure to films for 2 hours 
 
The incubation of formulations for 2 hours shows average cell viability ranging between 
38% and 49% for acetic acid, between 61% and 80% for lactic acid, and 90% for neutral 
Viscosan. Nevertheless, as it is apparent from Figure 32, the standard deviation is high in all 
the tested formulations. Although it may be assumed that the films containing lactic acid are 
gentler on the cells than the ones made with acetic acid, the statistical t-test does not show a 
significant difference (p>0.05) between the solvents used. Similarly, no differences were 
detected when using different types of chitosan. Even though the Viscosan, neutral chitosan, 
possesses the highest cell viability (90%), it cannot be confirmed that its effect on the cell 
viability is lower than when other formulations were used. For this reason, more parallels 
should be repeated to obtain more accurate results. 
The average results of the 24 hours incubation experiment with single film components are 
presented in Figure 33. A student t-test between the original and diluted samples showed no 
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to the low number of samples for each experiment and high variability. For this reason, no 
clear conclusions can be obtained on the effect of the formulation in respect to the 
concentration used.  
 
Figure 33: Cell viability (%) after exposure of HT29-MTX cells to film components for 2 hours 
 
On the other hand, the use of acids significantly lowers the cell viability indicating that 1% 
acid is very harsh on the cells. The t-test comparing original concentrations of the 
components proved the reduced cell viability when comparing both the acids to the other 
components, except for the chitosan L and HP-β-CD. Nevertheless, the test should be 
repeated to obtain clearer results as to whether the formulations affect the cell viability. 
The accuracy of results of an MTT test could be improved by adding a higher number of 

























From the obtained results, it may be concluded that different formulations and methods of 
preparation result in different physicochemical and mechanical properties of the produced 
dosage forms. 
• Films exhibit adequate mechanical and elastic properties suggesting a simple 
application of the product. Wafers were not tested due to the lack of method 
versatility but were considered appropriate for handling. 
• The interaction with the mucin is a crucial attribute in the production of 
mucoadhesive buccal films and wafers. The estimated mucoadhesion is highest for 
low molecular weight and water-soluble chitosan complying with the swelling 
abilities of those polymers. These formulations are expected to form the strongest 
interactions with the mucosal surface after the administration. 
• Wafers have a highly porous structure resulting in increased hydration and 
interaction with the mucin. The hydration ability is needed for the maximal exposure 
of adhesive sites to the mucosal surface.  
• In vitro prednisolone release follows the hydration profile having a slightly faster 
dissolution rate when using low molecular weight chitosan in lactic acid. Moreover, 
the change in compositions altered the release profile. A sustained release over five 
hours is achieved. 
• The permeability of prednisolone through the cell monolayer is good and suggests a 
ready absorption throughout the buccal mucosa. 
• A highly acidic pH may be toxic to the cells, irritate the site of application, and should 
be avoided in oral formulations. From this point of view, the use of water or acetic 
acid are more suitable solvents providing a more neutral pH of dosage forms than a 
stronger lactic acid. 
• Films were of an appropriate size and thickness and compelled with the requirements 
for the transparent, homogeneous, and soft film surfaces. The size and appearance of 
the wafer were considered suitable but lack a consensus on the optimal size and 
thickness of the oral films and wafers. 
• The organoleptic assessment is relevant due to the site of administration and the 
target population. The presence of acetic acid resulted in an unpleasant vinegar-like 
odor which may be unpleasant for dosage form administration. 
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Taking all the results into account, the experimental data suggest a successful development 
of novel dosage forms for delivery of a poorly water-soluble drug with mucoadhesive 
properties. Although there is no clear evidence of which formulation type is the most 
appropriate for the further development, it is apparent that the general desired characteristics 
have been achieved – including the mucoadhesive properties, a good permeability, suitable 
mechanical, and elastic properties, and acceptable dosage form size and thickness as well as 
a controlled drug release over a longer period.  
Nevertheless, the method still lacks reproducibility to provide a good uniformity between 
the samples. Since many of the parameters depend on the general dosage form prerequisites 
– mass and content uniformity – it is crucial to establish a robust method that would provide 
comparable characteristics. The challenges related to achieving a sufficient mass uniformity 
have been previously reported. Due to time limitations, the production method was not fully 
optimized. 
Despite the promising physicochemical and biopharmaceutical results obtained by 
characterization, the major challenge remains the transliteration of the in vitro results to in 
vivo situations where the additional factors influencing the drug delivery would be present. 
Hence, this information would provide us with a more realistic insight into the suitability of 
the drug delivery platforms developed. 
Generally, the developed formulations show a promising approach for the buccal delivery 
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